After the Global Initiative for Chronic Obstructive Lung Disease released updated recommendations for grading COPD patients’ level of disease in November of 2016, Imran Iftikhar, MD, FCCP, tried to incorporate them into his practice, but he encountered problems. For one thing, the new classification system, which became known as GOLD 2017, uncoupled spirometry results from the ABCD treatment algorithm. “I found it wasn’t really helping me in terms of prognostication or COPD management,” said Dr. Iftikhar, section chief of pulmonary and critical care at Emory Saint Joseph’s Hospital, Atlanta. “Although the purpose of the GOLD classification was not really meant for prognostication, most practicing physicians are frequently asked about prognosis by patients, and I am not sure if the 2017 reclassification really helps with that,” noted Dr. Iftikhar.

Asthma patients who struggle with poor control despite using inhaled corticosteroids can benefit from additional treatment with long-acting muscarinic antagonists (LAMAs) or single maintenance and reliever therapy, suggest data from a pair of systematic reviews and meta-analyses. Asthma control remains a problem for many patients despite the daily use of inhaled corticosteroids. The current preferred adjunct therapy for patients aged 12 years and older is long-acting beta-agonists (LABAs), wrote Diana M. Sobieraj, PharmD, of the University of Connecticut School of Pharmacy, Storrs, and her colleagues in a study published in JAMA. The researchers examined the efficacy of other adjunct therapies and therapeutic regimes, including the use of a LAMA, in two studies of patients with persistent asthma.

In one of their analyses, the researchers evaluated LAMAs as an add-on therapy for patients with poorly controlled asthma. They found that LAMAs provided significant clinical benefits, including reductions in asthma-related symptoms, hospitalizations, and exacerbations. The researchers concluded that LAMAs are a viable option for patients with persistent asthma who are not adequately controlled with current therapies.

In their second analysis, the researchers compared the efficacy of LAMAs to LABAs in patients with poorly controlled asthma. They found that LAMAs were non-inferior to LABAs in terms of asthma control, but provided additional benefits in terms of reduction in exacerbations.

The outcomes of ‘GOLD 2017’

“Most practicing physicians are frequently asked about prognosis by patients, and I am not sure if the 2017 reclassification really helps with that,” noted Dr. Imran Iftikhar.

**Adjunct treatments assist with persistent asthma**

**BY HEIDI SPLETE**

Asthma patients who struggle with poor control despite using inhaled corticosteroids can benefit from additional treatment with long-acting muscarinic antagonists (LAMAs) or single maintenance and reliever therapy, suggest data from a pair of systematic reviews and meta-analyses. Asthma control remains a problem for many patients despite the daily use of inhaled corticosteroids. The current preferred adjunct therapy for patients aged 12 years and older is long-acting beta-agonists (LABAs), wrote Diana M. Sobieraj, PharmD, of the University of Connecticut School of Pharmacy, Storrs, and her colleagues in a study published in JAMA. The researchers examined the efficacy of other adjunct therapies and therapeutic regimes, including the use of a LAMA, in two studies of patients with persistent asthma.

In one of their analyses, the researchers evaluated LAMAs as an add-on therapy for patients with poorly controlled asthma. They found that LAMAs provided significant clinical benefits, including reductions in asthma-related symptoms, hospitalizations, and exacerbations. The researchers concluded that LAMAs are a viable option for patients with persistent asthma who are not adequately controlled with current therapies.

In their second analysis, the researchers compared the efficacy of LAMAs to LABAs in patients with poorly controlled asthma. They found that LAMAs were non-inferior to LABAs in terms of asthma control, but provided additional benefits in terms of reduction in exacerbations.

The outcomes of ‘GOLD 2017’

“Most practicing physicians are frequently asked about prognosis by patients, and I am not sure if the 2017 reclassification really helps with that,” noted Dr. Imran Iftikhar.
New strains recommended for next flu season

BY IAN LACY

SILVER SPRING, MD. – In an effort to better match the vaccine to the virus, federal advisers have recommended two new strains be swapped into the 2018-2019 quadrivalent influenza vaccine. The updates should be the influenza A(H3N2) component and the influenza B components.

Singapore A(H3N2) and the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) are recommended be added to A/Michigan/45/2015 (H1N1)pdm09-like virus and B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) for the upcoming season, according to a near-unanimous vote at a meeting of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee.
Trivalent vaccines should include the same strains, with the exception of B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage), the committee recommended.

The panel voted separately on the strains, and all votes were unanimous, except for the vote on the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) in the trivalent vaccine, which was supported with 11 positive votes with 1 abstention.

The advisory committee’s recommendation is identical to the recommendations recently made by the World Health Organization for next season’s influenza vaccines in the Northern Hemisphere. The WHO recommended that trivalent vaccines contain A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus, and B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage). WHO also recommended that quadrivalent vaccines contain all of the above strains and B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) as the second influenza B strain.

Most of the influenza activity in the United States this season is due to influenza A(H3N2) viruses (67%), according to Lisa Grohskopf, MD, associate chief for policy & liaison in the Influenza Division at the Centers for Disease Control and Prevention. Fortunately, the majority of circulating strains are similar to those contained in the 2017-2018 vaccine. Only strains with B/Victoria lineage displayed antigenic drift, but represented less than 1% of all circulating viruses.

Hospitalization rates for laboratory-confirmed influenza this season have been markedly higher among people aged 65 years and older, compared with younger age groups, and have increased since last season. As of Feb. 17, the preliminary estimate of hospitalizations in this age group was 322.7 cases per 100,000 people, compared with about 290.5 per 100,000 during the 2016-2017 season. There have been 97 pediatric deaths associated with influenza, compared with 110 reported during the 2016-2017 season, 93 during 2015-2016, and 148 during 2014-2015.

With H3N2 strains of influenza A predominating, questions on the effectiveness of the newly recommended Singapore A(H3N2) were raised by the committee. Jacqueline Katz, PhD, director of the WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza, reassured the committee. “Yes, in fact, it does cover them very well. The majority of the viruses that we’ve tested at the CDC were that emerging 3C2a2 [clade of H3N2] group, and the Singapore virus covered those very well. In general, that’s why we went with Singapore,” she said.

Dr. Katz added that one of the reasons Singapore is so effective is because it can be found on the base of the phylogenetic tree; “it’s not on the tip of the tree where things are changing, so it’s a more conservative selection.”

The CDC estimate of current vaccine effectiveness (VE) against influenza A(H3N2) viruses is 25%, as of Feb. 3. Effectiveness is even higher for all influenza viruses, with an estimated VE of 36%, indicating that the flu vaccine reduced a person’s risk of having to seek medical care at a doctor’s office for flu illness by 36% (MMWR. 2018;67:180-5).

While the FDA usually follows the recommendations of its panel members, it is not obligated to do so. None of the committee members disclosed relevant financial conflicts of interest.
that clinicians derive ABCD groups exclusively from patient symptoms and their exacerbations. FEV$_1$ is an "important parameter at the population level" in predicting hospitalization and mortality, the authors wrote, but keeping results separate "will avoid misleading clinicians," Dr. Ouellette added.

In an analysis of the GOLD 2017 criteria applied to 819 COPD patients in Spain and the United States, published online Nov. 3, 2017, in the American Journal of Respiratory and Critical Care Medicine, Carlos Cabrera López, MD, and his colleagues concluded that the mortality risk was better predicted by the 2015 GOLD classification system than by the 2017 iteration (Am J Respir Crit Care Med. 2018 Feb. doi: 10.101164/rccm.201707-1363OC).

The distribution of Charlson index scores also changed. Where group D was higher than B in 2015, they become similar in the 2017 system. For her part, Dr. Han emphasized that the primary goal of the GOLD ABCD classification system is to categorize patients with respect to treatment groups. "Current therapy targets symptoms and exacerbations, which are the key current elements of the classification schema," she said in an interview. "The results of the Cabrera López analysis are not necessarily unexpected, as FEV$_1$ is associated with mortality."

In a prospective, multicenter analysis, Portuguese researchers compared the performance of GOLD 2011 and 2017 in terms of how 200 COPD patients were reclassified, the level of agreement between the two iterations, and the performance of each to predict future exacerbations (COPD. 2018 Feb;15[1]: 21-6). They found that about half of patients classified as GOLD D under the 2011 guidelines became classified as GOLD B when the 2017 version was used, and the extent of agreement between the two iterations was moderate (P less than .001). They also found that the two versions of the guidelines were equivalently

"Clinicians have indicated that they like the flexibility the system provides in separating spirometry, symptoms, and exacerbation risk as this more accurately reflects the heterogeneity we see in the COPD patient population," reported Dr. Han.

"acknowledges the limitations of FEV$_1$ in making treatment decisions for individualized patient care and highlights the importance of patient symptoms and exacerbation risks in guiding therapies in COPD." According to MeiLan Han, MD, MS, a member of the GOLD Science Committee, since release of the 2017 guidelines, "clinicians have indicated that they like the flexibility the system provides in separating spirometry, markers other than spirometry, such as eosinophil count, that clinicians with COPD," Dr. Ouellette added.

In a prospective, multicenter analysis, Portuguese researchers compared the performance of GOLD 2011 and 2017 in terms of how 200 COPD patients were reclassified, the level of agreement between the two iterations, and the performance of each to predict future exacerbations (COPD. 2018 Feb;15[1]: 21-6). They found that about half of patients classified as GOLD D under the 2011 guidelines became classified as GOLD B when the 2017 version was used, and the extent of agreement between the two iterations was moderate (P less than .001). They also found that the two versions of the guidelines were equivalently
predicted postbronchodilator FEV<sub>1</sub> more often and had a lower percent the 2017 iteration exacerbated 17% In addition, patients who met the 2017 iteration predicted mortality with greater accuracy, compared with previous iterations.

Continued from previous page
effective at predicting exacerbations (69.7% vs. 67.6% in the 2011 and 2017 iterations, respectively). In addition, patients who met the criteria for a GOLD B grouping in the 2017 iteration exacerbated 17% more often and had a lower percent predicted postbronchodilator FEV<sub>1</sub> than did those who met the criteria for a GOLD B classification under the 2011 guidelines.

Dr. Han, who is also an associate professor of medicine at the University of Michigan Hospital, acknowledged that GOLD 2017 has resulted in the reclassification of some previously group D patients as group B patients. “Our primary goal is to aid clinicians with the diagnosis and management of patients with COPD,” she said. “We look forward to additional data coming in from ongoing clinical trials that will provide longer term data to further refine treatment algorithms.”

In an recent study of more than 33,000 Danish patients older than age 30 with COPD, researchers led by Anne Gedebjerg, MD, found that the GOLD 2017 ABCD classification did not predict all-cause and respiratory mortality more accurately than previous GOLD iterations from 2007 and 2011. Area under the curve for the all-cause mortality was 0.61 for GOLD 2007, 0.61 for GOLD 2011, and 0.63 for GOLD 2017, while the area under the curve for respiratory mortality was 0.64 for GOLD 2007, 0.63 for GOLD 2011, and 0.65 for GOLD 2017 (Lancet Respir Med. 2018 Jan;6[3]:204-12).

However, when the spirometric stages 1-4 were combined with the A-D groupings based on symptoms and exacerbations, the 2017 classification predicted mortality with greater accuracy, compared with previous iterations (P < .0001). “My practice is very much like this paper,” Dr. Iftikhar said. “I use both the spirometric grade and the ABCD grouping to specify which group and grade my patient belongs to. I think future investigators need to combine ABCD with spirometry classification to see how we can improve the classification system.”

In a commentary published in the same issue of the Lancet Respiratory Medicine as the large Danish study, Joan B. Soriano, MD, PhD, wrote that the 2011 GOLD guideline’s collapse of four spirometric thresholds (greater than 80%, 50%-80%, 30%-50%, and less than 30%) into just two (greater than 50% or 50% or less) “reduced the system’s ability to inform and predict mortality from the short term up to 10 years” (Lancet Respir Med. 2018 Jan;6[3]:165-6).

“Lung function remains the best available biomarker for life expectancy in both patients with COPD and the general population,” wrote Dr. Soriano, a respiratory medicine researcher based in Madrid. conclusively shown to improve mortality. “The only things we know that improve mortality for COPD patients are quitting smoking and using oxygen if a patient meets predefined goals for oxygen,” he said. “So the fact that GOLD criteria doesn’t improve mortality shouldn’t make us think that it’s not a useful tool. We already know that the medicines may not help people live longer.”

Dr. Han pointed out that spirometry “is still used to further clarify the choice of therapy recommended based on the nature and degree of airflow obstruction in light of severity of patient symptoms. The data are still designed to be used in conjunction to personalize therapy for patients.”

She added that the GOLD Science Committee “welcomes additional data analyses so that future recommendations can be further refined.”

Dr. Han disclosed that she has consulted for Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. She has also received in-kind research support from Novartis and Sunovion.

Dr. Iftikhar reported having no financial disclosures. Dr. Ouellette is a member of CHEST Physician’s editorial advisory board. He disclosed being part of a federally funded study being carried out by the Patient-Centered Outcomes Research Institute.

There was no industry involvement in the GOLD 2017 report, but many of its authors and board members had pharmaceutical company ties, and GOLD’s treatment advice relies on data from industry-sponsored studies.

Dr. Daniel Ouellette remarked that “the fact that GOLD criteria doesn’t improve mortality shouldn’t make us think that it’s not a useful tool.”

When the spirometric stages 1-4 were combined with the A-D groupings based on symptoms and exacerbations, the 2017 classification predicted mortality with greater accuracy, compared with previous iterations.

GOLD 2017 ABCD classification vs. 2007 and 2011

<table>
<thead>
<tr>
<th></th>
<th>GOLD 2007</th>
<th>GOLD 2011</th>
<th>GOLD 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>0.61</td>
<td>0.61</td>
<td>0.63</td>
</tr>
<tr>
<td>(n = 33,765)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory mortality</td>
<td>0.64</td>
<td>0.63</td>
<td>0.65</td>
</tr>
<tr>
<td>(n = 22,621)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Subcohort of patients with cause-specific mortality data available.

Note: Based on data for patients aged 30 years or older from the Danish registry for COPD.

Source: Lancet Respir Med. 2018 Jan;6[3]:204-12

Mortality risk over 3 years by GOLD 2017 ABCD group

<table>
<thead>
<tr>
<th>Adjusted Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
</tr>
<tr>
<td>Respiratory mortality</td>
</tr>
</tbody>
</table>

Note: Based on data for patients aged 30 years or older from the Danish registry for COPD.

Source: Lancet Respir Med. 2018 Jan;6[3]:204-12

GOLD 2017 ABCD classification vs. 2007 and 2011

GOLD 2017 ABCD classification vs. 2007 and 2011

Continued from previous page
effective at predicting exacerbations (69.7% vs. 67.6% in the 2011 and 2017 iterations, respectively). In addition, patients who met the criteria for a GOLD B grouping in the 2017 iteration exacerbated 17% more often and had a lower percent predicted postbronchodilator FEV<sub>1</sub> than did those who met the criteria for a GOLD B classification under the 2011 guidelines.

Dr. Han, who is also an associate professor of medicine at the University of Michigan Hospital, acknowledged that GOLD 2017 has resulted in the reclassification of some previously group D patients as group B patients. “Our primary goal is to aid clinicians with the diagnosis and management of patients with COPD,” she said. “We look forward to additional data coming in from ongoing clinical trials that will provide longer term data to further refine treatment algorithms.”

In a recent study of more than 33,000 Danish patients older than age 30 with COPD, researchers led by Anne Gedebjerg, MD, found that the GOLD 2017 ABCD classification did not predict all-cause and respiratory mortality more accurately than previous GOLD iterations from 2007 and 2011. Area under the curve for the all-cause mortality was 0.61 for GOLD 2007, 0.61 for GOLD 2011, and 0.63 for GOLD 2017, while the area under the curve for respiratory mortality was 0.64 for GOLD 2007, 0.63 for GOLD 2011, and 0.65 for GOLD 2017 (Lancet Respir Med. 2018 Jan;6[3]:204-12).

However, when the spirometric stages 1-4 were combined with the A-D groupings based on symptoms and exacerbations, the 2017 classification predicted mortality with greater accuracy, compared with previous iterations (P < .0001). “My practice is very much like this paper,” Dr. Iftikhar said. “I use both the spirometric grade and the ABCD grouping to specify which group and grade my patient belongs to. I think future investigators need to combine ABCD with spirometry classification to see how we can improve the classification system.”

In a commentary published in the same issue of the Lancet Respiratory Medicine as the large Danish study, Joan B. Soriano, MD, PhD, wrote that the 2011 GOLD guideline’s collapse of four spirometric thresholds (greater than 80%, 50%-80%, 30%-50%, and less than 30%) into just two (greater than 50% or 50% or less) “reduced the system’s ability to inform and predict mortality from the short term up to 10 years” (Lancet Respir Med. 2018 Jan;6[3]:165-6).

“Lung function remains the best available biomarker for life expectancy in both patients with COPD and the general population,” wrote Dr. Soriano, a respiratory medicine researcher based in Madrid. Conclusively shown to improve mortality. “The only things we know that improve mortality for COPD patients are quitting smoking and using oxygen if a patient meets predefined goals for oxygen,” he said. “So the fact that GOLD criteria doesn’t improve mortality shouldn’t make us think that it’s not a useful tool. We already know that the medicines may not help people live longer.”

Dr. Han pointed out that spirometry “is still used to further clarify the choice of therapy recommended based on the nature and degree of airflow obstruction in light of severity of patient symptoms. The data are still designed to be used in conjunction to personalize therapy for patients.”

She added that the GOLD Science Committee “welcomes additional data analyses so that future recommendations can be further refined.”

Dr. Han disclosed that she has consulted for Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. She has also received in-kind research support from Novartis and Sunovion.

Dr. Iftikhar reported having no financial disclosures. Dr. Ouellette is a member of CHEST Physician’s editorial advisory board. He disclosed being part of a federally funded study being carried out by the Patient-Centered Outcomes Research Institute.

There was no industry involvement in the GOLD 2017 report, but many of its authors and board members had pharmaceutical company ties, and GOLD’s treatment advice relies on data from industry-sponsored studies.

Dr. Daniel Ouellette remarked that “the fact that GOLD criteria doesn’t improve mortality shouldn’t make us think that it’s not a useful tool.”

When the spirometric stages 1-4 were combined with the A-D groupings based on symptoms and exacerbations, the 2017 classification predicted mortality with greater accuracy, compared with previous iterations.
Four-gene signature predicted TB progression

BY AMY KARON
MDEdge News

The four-gene signature dubbed RISK4 performed similarly well in four diverse cohorts of HIV-negative household contacts of TB patients in sub-Saharan Africa, reported Sara Suliman, PhD, of the University of Cape Town, South Africa, and her associates. Testing for such a signature could be a cost-effective, point-of-care method to prioritize recipients of prophylactic treatment, the researchers said.

Worldwide, about 1.7 people are infected with Mycobacterium tuberculosis, but only 5%-20% of these individuals develop TB. Finding a reliable biomarker for increased risk of progression would be "an important step forward towards better TB control," especially in resource-strapped areas, the investigators said. Unfortunately, the predictive value of a positive tuberculin skin test or a positive interferon gamma release assay is too low to be useful for this purpose, they wrote in the American Journal of Respiratory and Critical Care Medicine.

Accordingly, the investigators searched for gene transcripts whose upregulation or downregulation reliably predicted progression to TB disease. To do so, they compared whole-blood PCR test results from 79 cases (who developed TB after exposure to a household index case) and 328 controls (household contacts who did not progress to TB disease). Progressors developed TB disease within 3-24 months of exposure. Nonprogressors were matched by site, sex, age, and year of recruitment.

The RISK4 signature comprised four unique genes: GAS6 and SEPT4, which were upregulated in progressors compared with matched controls, and CD1C and BLK, which were downregulated, the researchers reported. For the overall data set, RISK4 predicted TB progression with an area under the curve (AUC) of 0.67 (95% confidence interval, 0.57-0.77; P = .0002). The AUC for individual sites ranged from 0.66 to 0.72 (P less than .03) and was 0.69 (P = .0004) among household contacts who were tested within 2 months of index case diagnosis. Furthermore, RISK4 performed comparably in an external cohort, South African adolescents who tested positive on IGRA or TST (AUC, 0.69; 95% CI, 0.62 to 0.76; P = .0003)

The groups in this study represented diverse genetic backgrounds, TB epidemiology, and circulating strains of M. tuberculosis, which suggested that RISK4 reliably predicts TB progression among household contacts across sub-Saharan Africa, the researchers said. Previously published TB signatures (which include DIAG3, DIAG4, and ACS COR) performed as well as RISK4 on the overall test cohort, but not at individual sites, they added.

In unblinded post hoc analyses, two of the four transcripts (SEPT4 and BLK) performed as well as the four-gene RISK4 signature, according to the investigators. Upregulation of the complement C1q C-chain (C1QC) with downregulation of T-cell receptor alpha variable gene 27 (TRAV27) predicted progression even more reliably, with AUCs exceeding 0.76 at all study sites. However, this transcript pair did not perform as well in the separate adolescent cohort (AUC, 0.57).

"Importantly, samples from household contact progressors were collected mostly at enrollment, immediately following exposure to the respective TB index cases, thus possibly representing a signature of recent M.tuberculosis exposure," the researchers noted. "The next steps include assessment of the performance of RISK4 and the 2-transcript C1QC/TRAV27 signature in other settings, including non-African populations, and [determining] the feasibility of developing a near-patient test for targeted intervention."

Funding sources included the Bill and Melinda Gates Foundation, the National Institutes of Health, the South African Medical Research Council, the Carnegie Corporation of New York, the South African National Research Foundation, and the Claude Leon Foundation.


Good definitions, research lacking for COPD-asthma overlap

BY THOMAS R. COLLINS
MDEdge News

ORLANDO – Experts agreed that asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome, referred to as ACOS, is an area in dire need of more careful study to give clinicians data they can actually use.

The topic is even more pressing given the growing interest and research into biological treatments for asthma and consideration of their possible use in COPD, experts said at the joint congress of the American Academy of Allergy, Asthma, and Immunology and the World Asthma Organization. Their remarks came in what was ostensibly a “debate” on whether ACOS is a distinct entity requiring special treatment but largely turned into a discussion about gaps in knowledge on the topic.

The dilemma, they said, is that the research tends to look almost exclusively at extreme cases, with asthma studies excluding COPD patients and COPD studies excluding asthma patients.

“The problem here is that it has not been defined in a way that everyone agrees on – that does create a problem because, if there’s no consensus on the diagnostic criteria, then it may be difficult to study this overlap,” said Donald Tashkin, MD, director of the pulmonary function laboratories at the University of California, Los Angeles. “Because there is no agreement on how to diagnose ACOS, it hasn’t been studied with respect to its responsiveness to different treatment options."

R. Stokes Peebles Jr., MD, professor of allergy, pulmonary, and critical care medicine at Vanderbilt University Medical Center, Nashville, Tenn., said that, although the number of published articles on ACOS has skyrocketed over the last several years, review articles have outnumbered original research articles.

There is disagreement in published definitions: One set of definitions includes a criterion of fractional exhaled nitric oxide not seen in any other definitions, whereas some other definitions require a history of smoking while others don’t, he said.

“How does one manage a disease without a definition and without clinical studies? It’s impossible for me to know,” Dr. Peebles said.

A commentary piece published in 2016, he noted, called for the term ACOS to be “abandoned” and then replaced when new phenotypes and underlying subtypes are identified and when “a new taxonomy of airway diseases is generated.” Dr. Peebles said he agreed with this suggestion.

Jeffrey Drazen, MD, the Distinguished Parker B. Francis Professor of Medicine at Harvard Medical School, Boston, and the editor of the New England Journal of Medicine, also lamented the polar nature of the research. “We all treat patients in the middle; everybody does, all the time – and we would love more guidance,” he said.

Dr. Peebles

Dr. Tashkin
This advertisement is not available for the digital edition.
Multidisciplinary teams improve diagnoses in ILDs

BY RANDY DOTINGA
MDedge News

FROM THE JOURNAL CHEST® • New research provides strong statistical support for the use of dynamic multidisciplinary discussion in the diagnosis of patients who may have interstitial lung diseases (ILDs).

Multidisciplinary discussion (MDD) provided a diagnosis in 80% of referred cases when referring physicians couldn’t come up with one, and it changed the diagnosis in 41% of the other cases. The American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association adopted joint guidelines for the treatment of idiopathic pulmonary fibrosis (IPF) in 2015, and the ATS and ERS updated guidelines for the classification and terminology for idiopathic interstitial pneumonias in 2013. A previous study published in The Lancet Respiratory Medicine after these guidelines were adopted showed that, in IPF, MDDs lead to a “higher level of agreement on diagnoses, assign diagnoses with higher confidence more frequently, and provide diagnoses that have nonsignificant greater prognostic separation than do clinicians or radiologists in most cases” (Walsh SLF et al. 2016[4][7]:557-65).

In the new study, MDD failed to produce a diagnosis or suggestions about a way forward in only 3.5% of patients, according to the study, which appeared March 30 in CHEST®.

“Several previous studies have demonstrated that MDD improves the accuracy of ILD diagnosis, particularly as compared with the referring physician’s initial diagnosis,” said pulmonologist Danielle Antin-Ozerkis, MD, of Yale University, New Haven, Conn., in an interview. “The current study supports the use of this team approach.”

According to Dr. Antin-Ozerkis, accurate diagnosis of ILD is crucial to treatment, but it can be challenging to achieve. The MDD approach has been recommended since 2002 by the ATS and ERS, she said.

The study authors, led by Lauren J. De Sadeleer, MD, of Belgium’s University Hospitals Leuven, define the MDD approach as one “in which expert ILD clinicians, radiologists, and pathologists integrate all available clinical data, laboratory results, high-resolution computed tomography [HRCT] findings, and lung biopsy [when performed].”

For the study, the researchers tracked pre-MDD and MDD diagnoses of 938 consecutive patients with possible ILD who were discussed during 2005-2015. Of these patients, referring physicians made preliminary diagnoses in 49% of cases; in the rest, physicians either failed to develop a diagnosis or offered multiple possible diagnoses.

MDD teams produced a change in diagnosis in 191 – 42% – of patients with a pre-MDD diagnosis. Another condition was diagnosed in 118 of these patients, and the MDD teams declined to classify the other 73 patients pending further investigation.

The MDD teams also were able to produce diagnoses in 80% of cases when referring physicians could not come up with diagnoses.

“Discrepancy between pre-MDD diagnosis before work-up and discussion was remarkable,” the study authors wrote, estimating that MDD added value for 70% of referred patients.

“We believe MDD should be a common practice in the diagnosis of every patient with suspected ILD,” the researchers said.

The study doesn’t examine the challenges of putting MDD into practice, but Dr. Antin-Ozerkis provided some perspective. “It may be difficult for physicians to take the time from a busy practice to meet with a multidisciplinary team. It can require resources to gather the data necessary to comprehensively assess each patient case. Additionally, maintaining staff with experienced pulmonologists, radiologists and pathologists may be costly.”

She added that “there are various ways in which MDD may occur” and that the pros and cons of different methods have not been well studied. “This practice will likely evolve with the development of new biomarkers and other diagnostic strategies in IPF.”

Still, she said, “this joint undertaking is clearly vital in helping to guide clinical practice, including therapeutic decisions and discussion of prognosis. For now, any discussion between clinician, radiologist, and pathologist is of benefit.”

Eric Gartman, MD, FCCP, compared the use multidisciplinary discussions for diagnosing ILD to cancer tumor boards. “Similar to the concept of cancer tumor boards providing a multi-specialty approach to the evaluation and treatment of a complex disease, the benefit of utilizing a similar modality for interstitial lung disease patients can be substantial,” he said. “In addition to prior work, this study underscores the importance of these discussions and how they impact care, and potentially can alter a patient’s treatment and prognosis.”

A very important point is raised regarding access to such groups for a large segment of pulmonary practitioners – and novel mechanisms need to be established to ensure quality of care for these patients (e.g., an electronic multi-disciplinary review system or mandatory referral to an interstitial lung disease center),” added Dr. Gartman, who is an assistant professor of medicine at Brown University, Providence, R.I. and serves on the editorial advisory board for CHEST® Physician.

Research Foundation-Flanders and University Hospitals Leuven funded the study. Some study authors reported various disclosures. Dr. Antin-Ozerkis disclosed serving as an investigator on several clinical trials for IPF and other ILDs by Boehringer, Fibrogen, Promedior, and Roche. She noted that payments go directly to the university with no direct payments to the investigator.

This advertisement is not available for the digital edition.
This advertisement is not available for the digital edition.
reviewed data from 15 randomized clinical trials including 7,122 patients aged 12 years and older. Overall, patients who took a LAMA had a lower risk of asthma exacerbation requiring systemic corticosteroids and improved spirometry measures than did the patients who took a placebo or used another controller as an adjunct therapy.

In trials that compared LAMAs with placebo as an add-on to inhaled corticosteroids, LAMA patients experienced a significantly reduced risk of exacerbation requiring systemic corticosteroids (–1.8) and a significantly reduced risk of asthma worsening (–4.8). Another benefit seen in the patients who used a LAMA rather than those who used a placebo was improved spirometry measures, but the differences between these two patient groups’ numbers did not reach statistical significance.

The analysis also included studies that compared “triple therapy” – defined as use of a LAMA as add-on therapy to inhaled corticosteroids and LABAs – with use of LABA plus inhaled corticosteroids.

Triple therapy was significantly associated with improvements in rescue medication use vs. combined inhaled corticosteroids and LABAs, but not with a reduced risk of exacerbation. In addition, no significant differences appeared in Asthma Control Questionnaire-7 scores or overall Asthma Quality of Life Questionnaire scores between the two patient groups.

“Triple therapy was not significantly associated with improve-

ments in rescue medication use vs. combined inhaled corticosteroids and LABA therapy,” the researchers added.

The review of LAMAs used as add-on therapy was limited by several factors, including a primary focus on tiotropium, a lack of analysis of harms or the costs of the various therapies, the lack of data for children, and an inability to perform a subgroup analysis, the researchers said. Although LAMA use was associated with a lower risk of asthma exacerbation, compared with placebo use, the review could not adequately compare LAMA with controllers other than LABA, they added.

In the second analysis, which also was published in JAMA, the researchers evaluated the use of inhaled corticosteroids and LABAs for asthma exacerbations was seen in those who used the SMART protocol versus those who used a higher dose of inhaled corticosteroids and inhaled LABA as controller therapy. In addition, data from 341 children aged 4-11 years showed a –12% absolute difference in risk of asthma exacerbation with the SMART protocol.

In trials that compared patients using the SMART protocol with those taking only the dose of inhaled corticosteroids called for by SMART, the protocol was associated with an improvement in forced expiratory volume in 1 second (FEV₁) and a reduction in the need for rescue medication.

The SMART protocol also demonstrated advantages over taking the same dose of inhaled corticosteroid called for by SMART plus a LABA controller therapy or a higher dose of inhaled corticosteroids with a LABA controller therapy. Specifically, SMART patients experienced a –6.4% risk of asthma exacerbations, versus the first comparator group; and a –2.7% risk of asthma, compared with the group who took a higher dose of inhaled corticosteroids.
Triple therapy cuts COPD exacerbations

BY BIANCA NOGRADY
MEdge News

Triple therapy for chronic obstructive pulmonary disease (COPD) achieved reductions in moderate to severe exacerbations when compared with two kinds of dual therapy, in a study published online in the New England Journal of Medicine.

The trial compared the outcomes of COPD patients using an inhaled therapy comprising a corticosteroid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA) with the outcomes of similar patients taking one of two other therapy combinations—a corticosteroid and a LAMA or a LABA and a LAMA. This trial—Informing the Pathway of COPD Treatment (IMPACT)—included 10,355 patients with symptomatic COPD in 37 countries, according to David A. Lipson, MD, and his colleagues. IMPACT was the first study to compare a single inhaler triple therapy with two dual therapies, according to a statement made by Patrick Vallance, president of research and development at GlaxoSmithKline (GSK), when the Food and Drug Administration approved the triple therapy in September 2017.

The study randomized patients to 52 weeks of either triple inhaled therapy involving a once-daily combination of 100 mcg fluticasone furoate (a corticosteroid), 62.5 mcg of the LAMA umecilnium and 25 mcg of the LABA vilanterol; or dual inhaled therapy involving either 100 mcg fluticasone furoate plus 25 mcg of vilanterol, or 62.5 mcg of umecilnium plus 25 mcg of vilanterol. After 1 year, the rate of moderate to severe COPD exacerbations in the triple-therapy group was 0.91 per year, compared with 1.07 in the fluticasone furoate–vilanterol group and 1.21 in the vilanterol–umecilnium group. This translated to a 15% reduction with triple therapy compared with fluticasone furoate–vilanterol and a 25% reduction compared with vilanterol–umeclidinium (P less than .001 for both).

When the analysis was limited to severe exacerbations alone, the difference was significant only between the triple therapy, which GSK is marketing as Trelegy Ellipta, and the vilanterol–umeclidinium dual therapy. Dr. Lipson, of GSK and the University of Pennsylvania, and his coauthors noted that their finding of a greater benefit with the glucocorticoid-containing dual therapy, compared with the LABA-LAMA vilanterol–umeclidinium combination, contradicted the findings of the earlier FLAME trial. This was likely because of differences in patient populations and design, as all patients in the FLAME trial had a 1-month run-in treatment with the bronchodilator tiotropium, the researchers explained.

“Therefore any patients who would require an inhaled glucocorticoid may have had an increase in exacerbations and a decrease in lung function during the run-in period and would have been forced to leave the trial,” they wrote.

Patients with higher eosinophil levels seemed to do even better with triple therapy. In those with eosinophils above 150 cells per microliter or above, the annual rate of moderate to severe exacerbations was 0.95 with triple therapy, 1.08 with fluticasone furoate–vilanterol, and 1.39 with vilanterol–umeclidinium.

Triple therapy also was associated with a significantly longer time to first event and greater improvements in quality of life, compared with the dual therapies.

VIEW ON THE NEWS

New asthma guidelines needed

Asthma remains a major public health problem in the United States, but 11 years have passed since the last update to treatment guidelines, and an update to the current guidelines for asthma treatment is needed, wrote Jerry A. Krishnan, MD, FCCP, and David H. Au, MD, in an accompanying editorial (JAMA. 2018;319[14]:1441-3). “It is time to connect the efforts of the Food and Drug Administration, the evidence presented by Sobieraj et al., and the support from the National Asthma Education and Prevention Program to update the 2007 [Expert Panel Report 3] guidelines on asthma.”

Both reviews showed effectiveness for the treatments being assessed, compared with placebo, but each had limitations, the editorialists noted.

The study findings in the report on the efficacy of inhaled long-acting muscarinic antagonists (LAMAs) in adolescents and adults with uncontrolled asthma were limited by several factors including a focus primarily on tiotropium, absence of data on potential harms and relative costs of treatment, and a lack of data on children younger than 12 years, they noted. The findings in the analysis of the strategy known as Single Maintenance and Reliever Therapy (SMART) containing formoterol, a long-acting beta-agonist (LABA), were similarly limited by a lack of assessment of potential harm and data on children within the same age group, they said.

However, the effectiveness of the treatments seen in both reviews suggest that the forthcoming revision of the Expert Panel Report 3 guidelines on asthma from the National Asthma Education and Prevention Program should include the option for inhaled tiotropium, a LAMA, and for the formoterol-based SMART protocol, the editorialists wrote.

“For patients and clinicians, the results from these meta-analyses suggest that dual therapy with scheduled doses of inhaled corticosteroids and LABA or inhaled corticosteroids and LAMA should help reduce the risk of future asthma exacerbations in patients with inadequate asthma control while using inhaled corticosteroids alone,” they said. The new guidelines should include evidence for the SMART protocol as well, but “studies assessing the efficacy of SMART using combination formoterol and budesonide via a metered-dose inhaler are needed,” they concluded.

Dr. Krishnan is affiliated with the division of pulmonary, critical care, sleep, and allergy at the University of Illinois, Chicago, and disclosed having received compensation from Sanofi for participation on an independent data-monitoring committee. Dr. Au is affiliated with the division of pulmonary, critical care, and sleep medicine at the University of Washington, Seattle, and disclosed having received compensation from Novartis for participation on a data-monitoring committee and for serving as a consultant to Gilead Sciences.
LAMA-LABA group, they wrote.

rate of exacerbations in the inhaled glucocorticoids would have con-

ized to the vilanterol-umeclidinium glucocorticoid who were random-

that any patients taking an inhaled glucocorticoid. The authors noted

py and 29% were taking an inhaled glucocorticoid. The rates of seri-

ol-umeclidinium group. The rates of serious adverse events in each
group were 22%, 21%, and 23%, respectively.

of the division of pulmonary and critical care medicine at New York-

Presbyterian Hospital/Weill Cornell Medical Center, said the study ad-

vanced the understanding of COPD management by addressing some

key evidence gaps, in a statement issued by GSK.

“By comparing various combinations of effective medications

the same device, the study clarifies which type of patient gains
greatest benefit from each class of medicine,” Dr. Martinez said in
the statement. “As many patients experience frequent exacerbations or
‘flare ups,’ which can often result in hospitalization, these data will be
highly relevant to patients and clini-
cians as they consider the optimal treatment.”

The study was funded by GSK, which manufactures Trelegy Ellip-
ta triple therapy for COPD. Eight authors were employees of GSK
and two were on advisory boards for the company. Seven authors
declared funding from a range of pharmaceutical companies includ-
ing GSK. One author had no con-

icts of interest to declare.

chestphysiciannews@chestnet.org


More data on COPD triple therapy, but questions remain

The data from the IMPACT study fills a gap in the evidence support-
ing a step-up from dual to triple inhaled therapy for COPD, which
so far has been recommended only for patients with severe loss of
lung function and those with frequent exacerbations despite max-
imum bronchodilator treatment. The study has the strengths of
comparing the step-up to triple therapy with the GOLD guideline-
recommended dual therapies and using the same dosages in the
triple therapy as in the dual therapy.

However, it is important to note that nearly 40% of patients enrolled
in the trial were already being treated with triple therapy, 70% were
receiving a glucocorticoid, and patients with a history of asthma were
not excluded. This means patients assigned to the dual therapy with-
out glucocorticoids would have had an abrupt cessation of their gluco-
corticoid therapy, which may explain a rapid surge in exacerbations in
the first month and the lower rate of exacerbations in the dual-therapy
group that did include glucocorticoids. The choice of patients for the
study could potentially have artificially inflated the observed effective-
ness of triple therapy over dual bronchodilator treatment.

As such, we suggest clinicians stick with the GOLD 2017 recom-
mandations that escalation to triple therapy only occur after maxi-
mization of bronchodilator treatment.

Samy Suissa, PhD, is with the Center for Clinical Epidemiology at Lady Davis
Institute–Jewish General Hospital, and the departments of epidemiology and
biostatistics and medicine at McGill University, Montreal. Jeffrey M. Drazen,
MD, is editor-in-chief of the New England Journal of Medicine. These com-
ments are taken from an editorial (N Engl J Med. 2018 Apr 18. doi: 10.1056/
NEJMe1716802). Dr. Suissa declared personal fees and grants from the phar-
maceutical industry outside the submitted work.

New Live Learning Courses!

The 2018 lineup of CHEST Live Learning courses features
three new additions. Continue to build your skills with the
most relevant, hands-on chest education designed for the
whole critical care team.

Lung Cancer: Physiologic Assessment and Optimization
Prior to Therapy - A Multidi-

plinary Course
July 13-15

Extracorporeal Support for Respiratory and Cardiac Failure in Adults
December 7-9

Complete Details
livelearning.chestnet.org

Board Review 2018
August 10-19 | Austin, Texas

How will you prep for your 2018 board exams? Let CHEST help you prepare live and in-person for next year’s pulmonary, critical care, and pediatric pulmonary exams with our comprehensive review courses.

As always, CHEST board review courses offer thorough exam prep you can put to the test.

Reserve Your Seat
boardreview.chestnet.org
Switch to mepolizumab safe in eosinophilic asthma

BY NICK ANDREWS
MDedge News

ORLANDO – Switching to mepolizumab resulted in a clinically significant benefit and a reduction in exacerbations for patients with severe eosinophilic asthma, according to late-breaking research presented at the joint congress of the American Academy of Allergy, Asthma, and Immunology and the World Asthma Organization.

Frank C. Albers, MD, PhD, of GlaxoSmithKline in Chapel Hill, N.C., and his colleagues examined safety and efficacy outcomes for 145 patients aged 12 years or older with severe eosinophilic asthma (SEA) that was not well controlled with omalizumab.

“You see similar research in oncology where, if a patient doesn’t respond, you want to try a switch,” Dr. Albers said in an interview. “The key is deciphering which patients would benefit from a switch.”

The researchers discontinued omalizumab at baseline and treated patients with 100 mg of mepolizumab every 4 weeks for 28 weeks and observed patients for 4 more weeks following last treatment. They examined Asthma Control Questionnaire-5 and St. George’s Respiratory Questionnaire results. In a secondary analysis, the researchers also compared their results with placebo-arm data from previously published research.

At 32 weeks, the least-squares mean ACQ-5 score changed by -1.45 (+/- 0.107) points and the SGRQ scores changed by -19.0 (+/- 1.64) points. “The response appears to happen quickly,” Dr. Albers said. “But you also see that the improvement seems steady.”

At 4 weeks, 57% of patients experienced a minimum clinically important difference in ACQ-5 score and at 12 weeks, 69% of patients experienced a minimum
clinically important difference in SGRQ response. At 32 weeks, minimum clinically important difference ACQ-5 and SGRQ scores were reported for 77% and 79% of patients, respectively.

Dr. Albers and his colleagues also analyzed how these results might look in a randomized phase 3 setting by comparing their results to previously reported data from the MENSA (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) and DREAM (epolizumab for severe eosinophilic asthma) studies.

They reported that, compared with the previously reported placebo cohorts, patients who switched to mepolizumab experienced an ACQ-5 score improvement of –0.90 (P less than 0.001). The researchers presented safety results in an accompanying poster and reported a 65% (P less than 0.001) reduction in the rate of clinically significant exacerbations for patients with SAE who switched to mepolizumab. They also reported a 69% (P less than 0.001) reduction in exacerbations that required ED visits and/or hospitalizations.

“This study provides practical reassurance to clinicians considering substituting one biologic for another in the treatment of patients with SEA,” the researchers concluded. This research was funded by GlaxoSmithKline, the makers of mepolizumab.

chestphysiciannews@chestnet.org
App links symptoms to local airborne triggers

BY THOMAS R. COLLINS
MDedge News

ORLANDO — Use of an app combining patient-reported symptoms with local environmental triggers led patients to take action to improve their health, Penny Jones, PhD, reported at the joint congress of the American Academy of Allergy, Asthma, and Immunology and the World Asthma Organization.

AirRater is a smartphone app and data collection network that includes information on air particulates, daily pollen and fungi counts, temperature, and planned burn locations. Patients enter their respiratory symptoms, which are correlated with local environmental conditions, according to Dr. Jones, a postdoctoral fellow at the University of Tasmania (Australia) in Hobart.

Most of the environmental data are gathered from government agencies; however, researchers collect pollen and fungi counts at their own stations.

Patients do not see the environmental data until they’ve logged in their symptoms so that their reports aren’t biased by that information, Dr. Jones said, adding that the app also sends notifications when pollen and pollutant levels are high.

“It’s an environmental monitoring system coupled with a smartphone app designed to help people with allergies and asthma make better decisions around their health,” Dr. Jones said.

The AirRater network and app are now operating in both Tasmania and Canberra, Australia.

There are more than 6,000 users, and data from surveys show that it is having an effect, Dr. Jones said. About 40% of users said they have changed their behavior in some way because of information provided by the app, including staying indoors, taking preventive medication, or speaking with their doctors. “It does appear that people are generally finding it a useful tool,” she said.

In a pilot study, researchers found that several environmental triggers were significantly correlated with exacerbation of patient symptoms, including maximum temperature ($P < .001$), particulate pollution ($P < .001$), relative humidity ($P = .01$), birch pollen ($P = .006$), and cypress pollen ($P = .004$).

Researchers plan to expand use of the network and app to other parts of Australia and are working to refine the understanding of aerobiological symptom drivers through DNA analysis of airborne particles. Their goal is to be able to identify personalized drivers of sensitivities, she said.

“We’ll keep working on this,” Dr. Jones said. “But we think that certainly has promise.”

The investigators reported no financial conflicts of interest.

The study received no outside funding.

chestphysiciannews@chestnet.org
PULMONARY MEDICINE

Asthma flourishing among health care, social workers

BY RICHARD FRANKI
MDedge News

Workers in the health care and social assistance industry are more likely to have asthma than those in any other segment of the American economy, according to the Centers for Disease Control and Prevention. Current asthma prevalence was 8.8% for adults aged 18 years and older who worked in health care and social assistance in 2011-2016, which put them above those in education services (8.2%); arts, entertainment, and recreation (8.1%); accommodation and food services (7.7%); and finance and insurance (7.5%). The overall rate for all working adults was 6.8%. Jacek M. Mazurek, MD, PhD, and Girija Syamlal, MBBS, reported in the Morbidity and Mortality Weekly Report.

“New-onset work-related asthma in [health care] workers has been associated with exposure to cleaning and disinfecting products, powdered latex gloves, and aerosolized medications,” they wrote. Among persons with asthma who were employed in health care and social assistance, 45.8% reported having at least one asthma attack in the previous year. Among the subgroups of the industry, those working in hospitals were highest with a 51.7% rate of past-year asthma attacks, followed by those working in nursing and residential care facilities at 45.2%, those working in ambulatory health care services at 43.2%, and those working in social assistance at 42.9%. The highest asthma attack rates among all industries were 57.3% for wood product manufacturing and 56.7% for plastics and rubber products manufacturing, the investigators said, based on data from the National Health Interview Survey.

Asthma-related visits to the emergency department in the past year were much less common for those in health care – 11.3% overall – and followed a pattern different from asthma attacks. Those working in nursing and residential care facilities were highest at 13.8%, with those in social assistance at 12.3%, those in ambulatory care at 10.5%, and those in hospitals the lowest at 10.1%. The highest ED-visit rate for any industry, 22.9%, was for workers in private households, said Dr. Mazurek and Dr. Syamlal, both of the respiratory health division at the CDC’s National Institute for Occupational Safety and Health in Morgantown, W.Va.


Talc administration improves indwelling catheter outcomes

BY ANDREW D. BOWSER
MDedge News

Patients with malignant pleural effusion treated with an indwelling pleural catheter have an improved chance of a positive outcome when talc administration is part of their procedure, suggest the results of a randomized, placebo-controlled study.

Malignant pleural effusion, which is usually caused by the spread of metastatic cancer, is typically treated by induction of pleurodesis. Talc is probably the most effective agent for achieving this result, but there are drawbacks to using talc to induce pleurodesis. Patients who receive this treatment often need to stay in the hospital for 4-7 days, according to Rahul Bhatnagar, PhD, and the coauthors of a study published in the New England Journal of Medicine. Indwelling pleural catheters provide an “ambulatory alternative” for fluid management, they noted. In a noncomparative series of 22 patients, administering talc through such a catheter produced high rates of pleurodesis, they added.

In the new study, Dr. Bhatnagar of the Academic Respiratory Unit, University of Bristol (England) and his coauthors evaluated the use of an indwelling catheter, with or without talc, in patients with malignant pleural effusion recruited at 18 centers in the United Kingdom over 4 years.

“Our primary-outcome results, which were backed up by robust sensitivity analyses, strongly suggest that the administration of talc through an indwelling pleural catheter was significantly more efficacious than the use of an indwelling pleural catheter alone among patients without substantial lung entrapment,” the authors wrote.

A total of 154 patients underwent randomization to the talc or placebo group, and 139 had sufficient data to evaluate the primary outcome of successful pleurodesis at 35 days after randomization. The researchers excluded patients with evidence of lung entrapment, or nonexpandable lung, according to the study report.

At day 70, the success rate was 51% for the talc group vs. 27% for the placebo group, respectively. The rate of pleurodesis was significantly higher when talc was administered through an indwelling pleural catheter, Dr. Bhatnagar and his colleagues noted.

“Success rates at day 70 suggested that pleurodesis was maintained to a point that is clinically relevant for patients with short median survival,” they added.

No excess of side effects or catheter blockages were associated with talc vs. placebo administration through a catheter. Additionally, no differences were seen between the talc and placebo groups in the number of adverse events, number of inpatient days, mortality, or other outcomes tracked by the researchers.

Dr. Bhatnagar reported he had no disclosures related to the study. Study coauthors reported disclosures related to Becton Dickinson – CareFusion, Rosetrees Trust, GE Medical, and Rocket Medical.

Becton Dickinson supported the trial with an unrestricted research grant and supplied catheters and drainage bottles for the study’s participants.

Don’t use cannabis to treat OSA, AASM recommends

BY KATIE WAGNER LENNON
MDedge News

The American Academy of Sleep Medicine (AASM) opposes the use of medical cannabis and its synthetic extracts for treating obstructive sleep apnea, according to a position statement published in the Journal of Clinical Sleep Medicine’s April issue.

In the statement, the professional society recommends that state legislators, regulators, and health departments exclude obstructive sleep apnea (OSA) as an indication for medical cannabis programs.

“The unreliable delivery methods and insufficient evidence of treatment effectiveness, tolerability, and safety” of medical cannabis and its synthetic extracts are among the reasons the AASM gave for making its recommendations. “Further research is needed to better understand the mechanistic actions of medical cannabis and its synthetic extracts, the long-term role of these synthetic extracts on OSA treatment, and harms and benefits,” the AASM concluded in its statement.

Impact of sleep loss on metabolism is highly individualized

BY CHRISTOPHER PALMER
MDedge News

Shift work – and the various light exposures that go with it – can place some people at a greater risk of weight gain and obesity. But the impact of various light exposures inherent in shift work appear to affect the metabolism of each person differently, reported Edward L. Melanson, PhD, and his coinvestigators.

“Such individual differences were not explained by sex, age, weight, fat mass, or fat free mass,” Dr. Melanson and his coinvestigators wrote. “Thus, understanding mechanisms underlying such individual differences in wakening and sleep energy metabolism and how they may or may not contribute to health outcomes ... requires additional research.”

The investigators’ conclusions are based on the results of two studies. Both studies used whole-room, indirect calorimetry to measure energy expenditure. The participants, all of whom were free of medications and illicit drugs, maintained a consistent 8-hour sleep schedule before the study took place, and consumed a specified diet throughout the study. Meal tests were used to assess the participants’ glucose metabolism responses, a protocol cited as one of the study’s limitations.

The first study, comprising 15 healthy young adults, looked for changes in energy expenditure and glucose metabolism in response to different lighting conditions, such as full-spectrum bright light or blue-enriched bright light. In that study, no effects were found on patients’ metabolism.

The other study, comprising 14 healthy young adults, looked for changes in energy expenditure and how they may or may not contribute to health outcomes. In this trial reported at least one adverse event, with the rates having not differed significantly between the treatment and placebo arms. The most frequently reported adverse events were “sleepiness/drowsiness” (n = 25; 8% of total adverse events reported), headache (n = 24; 8%), “nausea/vomiting” (n = 23; 8%), and “dizziness/lightheadedness” (n = 12; 4%). In addition, one patient experienced diarrhea and vomiting that required admission to a hospital, which was judged as possibly related to the study medication. There were six other withdrawals due to adverse events, including dizziness and vision changes, vertigo, ECG arrhythmias, and headache with dizziness and vomiting.

“Synthetic medical cannabis may have differential side effects, with variable efficacy and side effects in the treatment of OSA. Therefore, it is the position of the American Academy of Sleep Medicine that medical cannabis and/or its synthetic extracts should not be used for the treatment of OSA,” Dr. Ramar and his associates wrote.


Study: Caffeine shown safe in apnea of prematurity

BY AMY KARON
MEdge News

Caffeine for apnea of prematurity was neurobehaviorally safe and significantly improved fine motor coordination, visuomotor integration, visual perception, and visuospatial organization at 11-year follow-up, according to the results of a double-blind, randomized, controlled trial.

“There was little evidence for differences between the caffeine and placebo groups on tests of general intelligence, attention, executive function, and behavior. This highlights the long-term safety and efficacy of caffeine therapy for apnea of prematurity in very-low-birth-weight neonates,” wrote Ines M. Mürner-Lavanchy, PhD, of Monash University, Clayton, Australia, and her associates. The Caffeine for Apnea of Prematurity (CAP) trial, the first to assess long-term neurobehavioral outcomes of neonatal caffeine therapy, was published online April 11 in Pediatrics.

Apnea of prematurity affects more than half of preterm neonates. Respiratory stimulation with caffeine therapy is standard care, having been shown to improve disability-free survival and gross motor skills. In this randomized, multicenter, double-blind trial, very-low-birth-weight infants (500-1,250 g) received either normal saline placebo or caffeine citrate (20-mg/kg loading dose, followed by 5-mg/kg daily maintenance dose; could be increased to up to 10 mg/kg for refractory apnea). Patients started treatment at a median of 3 days and were weaned off by postmenstrual age 35 weeks.

Neonatal caffeine therapy significantly lowered the risk of death before 18 months, cerebral palsy, cognitive delay, severe hearing loss, and bilateral blindness, as has been reported (N Engl J Med. 2007;357:1893-902). By 5 years, caffeine no longer showed significant benefits, apart from improved motor performance, Dr. Mürner-Lavanchy and her associates noted.

At 11 years, available data from 870 patients showed generally similar neurobehavioral outcomes between groups, although the caffeine group scored higher on most scales. The most apparent benefits included visuomotor integration (mean difference from placebo, 1.8; 95% confidence interval, 0.0-3.7; \( P < .05 \)), visual perception (2.0; 95% CI, 0.3-3.8; \( P = .02 \)), fine motor coordination (2.9; 95% CI, 0.7-5.1; \( P = .01 \)), and Rey Complex Figure copy accuracy, a measure of visuospatial organization (1.2; 95% CI, 0.4-2.0; \( P = .003 \)).

Eleven-year follow-up data were missing for 22% of patients, but their birth characteristics and childhood outcomes resembled those of patients with available data, the investigators said. “Therefore, we are confident that the outcomes of the whole cohort are reflected in the present results with sufficient accuracy.”

The Canadian Institutes of Health Research provided funding. The investigators reported having no relevant conflicts of interest.


CPAP may help stroke patients with obstructive sleep apnea

BY ANDREW D. BOWSER
MEdge News

For stroke patients with obstructive sleep apnea using continuous positive airway pressure (CPAP) may improve stroke outcomes and reduce the recurrence of vascular events, the results of a randomized study suggest.

Obstructive sleep apnea is present in 50%-80% of patients with stroke, previous studies show, and its presence is associated with impaired function and cognition, delirium, and longer rehabilitation time, among other negative impacts, wrote Anupama Gupta, PhD, and her coauthors from the All India Institute of Medical Sciences, New Delhi, in the Journal of Clinical Sleep Medicine. Although multiple trials have shown a positive effect of CPAP on stroke recovery, relatively few investigations have looked specifically at whether the intervention prevents subsequent vascular events.

This study included 70 patients with first arterial stroke at least 6 weeks after the event and moderate to severe obstructive sleep apnea (OSA). These patients were randomized to be treated with CPAP or standard medical care. Initially, 34 patients were treated with CPAP and 36 were treated with standard care. Four of the patients receiving CPAP crossed over to the control group during the trial.

Patients’ clinical stroke outcomes were categorized in accordance with the Modified Rankin Scale (mRS), which is most widely used to assess disability and dependence outcomes among patients with stroke.

Significantly more patients who were treated with CPAP experienced an improvement in their mRS score by at least 1 point, when assessed at both 6 and 12 months following entrance into the study. Specifically, 53% (16) of patients in the CPAP group had an improvement of at least 1 point in their mRS score at 12 months, compared with 27% (11) of patients who did not use CPAP (\( P = .03 \)).

“These differences are statistically significant, as well as clinically meaningful and relevant,” Dr. Gupta and her colleagues said in their report.

This finding was consistent with what researchers have seen in some earlier studies of stroke patients who used CPAP, the researchers wrote.

Additionally, CPAP-treated patients had fewer subsequent vascular events, compared with those who did not use CPAP, though the difference did not reach statistical significance. There was only one new vascular event (3.3%) in the CPAP group at 12-month follow-up, versus six events (15%) in the non-CPAP group (\( P = .23 \)).

Nevertheless, the results provide more evidence for the potential benefit of CPAP in stroke patients with obstructive sleep apnea, the researchers noted.

“Our results indicate that new vascular events may be better prevented – and significantly more patients may make good stroke recovery – with CPAP treatment as compared to only best medical treatment,” Dr. Gupta and her colleagues wrote.

Before the study started, investigators determined that they would have needed 80 patients per arm for a power of 80%. A total of 679 patients were screened, but only 116 reported for polysomnography testing, and of those, 83 had at least moderate obstructive sleep apnea.

Because of a lack of CPAP devices, only 70 of those 83 patients made it all the way to randomization, investigators reported. Dr. Gupta and her coauthors reported no conflicts of interest related to the study.

Cigarette smoking is an important risk factor for heart failure in blacks, according to results of an investigation of patients in the Jackson Heart Study.

Current smoking among blacks was associated with higher mean left ventricular (LV) mass and lower mean LV systolic function, even after adjustment for confounding factors, authors of the analysis reported in the journal Circulation.

Hospitalization for heart failure among blacks was associated not only with current smoking but also with smoking intensity, measured in cigarettes per day, and smoking burden, measured in pack-years, reported Daisuke Kamimura, MD, PhD, of the University of Mississippi Medical Center, Jackson, and associates.

While blacks are known to have a higher incidence of heart failure than do whites, Hispanics, and Asians, this is believed to be the first prospective study of a large black cohort demonstrating a dose-response relationship between smoking and incident heart failure.

“Smoking cessation may be a potential strategy to attenuate the higher rate of heart failure in blacks,” wrote Dr. Kamimura and coauthors.

The published analysis included data on 4,129 participants in the Jackson Heart Study, a large, prospective, community-based observational study investigating cardiovascular risk factors in blacks.

That group, which was 63% female, included 503 current smokers, 742 former smokers, and 2,884 individuals who had never smoked.

At baseline, no patients had a history of heart failure or coronary heart disease, and over a median follow-up of 8.0 years, there were 147 hospitalizations for heart failure in the cohort, the investigators reported.

Current smoking, compared with never smoking, was significantly associated with incident heart failure hospitalization after adjusting for risk factors and coronary heart disease (hazard ratio, 2.82; 95% confidence interval, 1.71-4.64).

Likewise, smoking intensity of at least 20 cigarettes a day (HR, 3.48; 95% CI, 1.65-7.32) and smoking burden of at least 15 pack-years (HR, 2.06; 95% CI, 1.29-3.33) both were significantly associated with incident heart failure hospitalization.

Compared with never smoking,
current smoking was significantly associated with higher mean LV mass index and lower mean LV circumferential strain, even after adjusting for confounding variables (P less than 0.05 for both comparisons).

Smoking status also was associated with higher mean levels of brain natriuretic peptide, as were smoking intensity and burden (P less than 0.05 for all three comparisons), data show.

While cigarette smoking is a well-known risk factor for cardiovascular disease, the influences on cardiac structure and function may not be fully appreciated because of the strong association with coronary heart disease, a major cause of heart failure, the authors noted.

The Jackson Heart Study is supported by Jackson (Miss.) State University, Tougaloo College, and the University of Mississippi Medical Center, all in Jackson, contracts from the National Heart, Lung, and Blood Institute and the National Institute for Minority Health and Health Disparities. This study was supported by the NHLBI. One author has also received support from the National Institute of Diabetes and Digestive and Kidney Diseases and The National Institute of General Medical Sciences.

ORLANDO – In what was hailed as a major advance in preventive cardiology, the ODYSSEY Outcomes trial has shown that adding the PCSK9 inhibitor alirocumab on top of intensive statin therapy reduced major adverse cardiovascular events and all-cause mortality significantly more than placebo plus intensive statin therapy in patients with a recent acute coronary syndrome and an elevated on-statins LDL cholesterol level.

The study findings suggest the key to improving outcomes in ACS patients is to drive their LDL cholesterol level below 50 mg/dL, P. Gabriel Steg, MD, said in presenting the results at the annual meeting of the American College of Cardiology. ODYSSEY Outcomes was a double-blind trial in which 18,924 patients...
Patients at 1,315 sites in 57 countries were randomized to alirocumab (Praluent) or placebo plus background high-intensity statin therapy starting a median of 2.5 months after an acute coronary syndrome. All participants had to have a baseline LDL cholesterol level of 70 mg/dL or higher despite intensive statin therapy. Alirocumab was titrated to maintain a target LDL of 25-50 mg/dL. An LDL of 15-25 mg/dL was deemed acceptable, but if the level dropped below 15 mg/dL on two consecutive measurements the patient was blindly switched to placebo, as occurred in 7.7% of the alirocumab group.

The primary study endpoint was a composite outcome comprising CHD (coronary heart disease) death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization. During a median 2.8 years of follow-up, this outcome occurred in 9.5% of the overall population randomized to alirocumab and 11.1% of those on placebo, for a statistically significant and clinically meaningful 15% reduction in relative risk. The CHD death rates in the two study arms were similar; however, the other three components of the primary endpoint occurred significantly less often in the alirocumab group: The risk of nonfatal MI was 14% less (6.6% vs. 7.6%), ischemic stroke was 27% less (1.2 vs. 1.6%), and unstable angina was 39% less (0.4% vs. 0.6%).

All-cause mortality occurred in 3.5% of patients receiving alirocumab and 4.1% on placebo, once again for a statistically significant 15% reduction in risk. This was a major achievement, since even statins haven’t shown a mortality benefit in the post-ACS setting, observed Dr. Steg, cochair of the study.

The greatest benefits were seen in the 5,629 participants with a baseline LDL of 100 mg/dL or more on high-intensity statin therapy. In this large subgroup at highest baseline risk, alirocumab resulted in an absolute 3.4% risk reduction and a 24% reduction in relative risk of major adverse cardiac events (MACE). All-cause mortality decreased by an absolute 1.7%, translating to a 29% relative risk reduction. The number-needed-to-treat (NNT) for the duration of the study in order to prevent one additional MACE event in this group was 29, with an NNT to prevent one additional death of 60, added Dr. Steg, professor of cardiology at the University of Paris and chief of cardiology at Bichat Hospital.

“The risk/benefit for alirocumab is extraordinarily favorable. There was almost no risk over the course of the trial. There was no increase in neurocognitive disorders, new-onset or worsening diabetes, cataracts, or hemorrhagic stroke,” the cardiologist said.

Indeed, the sole adverse event that occurred more frequently in the alirocumab group was mild lo-
cal injection site reactions, which occurred in 3.8% of the alirocumab group and 2.1% of controls.

There was a tendency for LDL to creep upward in both the alirocumab and placebo arms over the course of follow-up. Dr. Steg attributed this to downtitration or cessation of alirocumab as per protocol along with the inability of a substantial proportion of patients to tolerate intensive statin therapy. Most study participants had never been on a statin until their ACS.

A year ago at ACC 2017, other investigators presented the results of FOURIER, a large clinical outcomes trial of evolocumab (Repatha), another PCSK9 (pro-protein convertase subtilisin/kexin type 9) inhibitor. FOURIER also showed a 15% relative risk reduction in major adverse cardiovascular events, but unlike in ODYSSEY Outcomes, there was no significant impact upon mortality. Dr. Steg attributed this to several key differences between the two trials. The post-ACS population of ODYSSEY Outcomes was on average higher-risk than FOURIER participants, who had stable atherosclerotic cardiovascular disease. The background statin therapy was more intensive in ODYSSEY, and the average follow-up was close to 8 months longer, too.

Session cochair Valentin Fuster, MD, declared, “I believe this trial is going to change practice. It’s a hypothesis that has been fulfilled.”

The study population is representative of an enormous number of patients seen in clinical practice, added Dr. Fuster, professor of medicine and physician-in-chief at Mount Sinai Hospital in New York. He estimated that one-third of patients who experience ACS can’t subsequently get their LDL down to the 70-mg/dL range on statin therapy, generally because of drug intolerance.

He voiced a concern: “Up until now, the feasibility and affordability of using this type of drug has been extremely difficult. I hope this particular study is a trigger – a catalyst – for making this drug much more available to people who need it.”

The study met with an enthusiastic audience reception. Prior to presentation of the results at the meeting’s opening session, 79% of the audience of more than 4,000 in the main arena indicated they either don’t prescribe PCSK9 inhibitors or do so only a handful of times per year. Immediately after seeing the data, 62% of the audience said their practice will change as a result of the study findings.

ODYSSEY Outcomes was funded by Sanofi and Regeneron Pharmaceuticals. Dr. Steg reported serving as a consultant to and receiving research grants from those pharmaceutical companies and numerous others.
ORLANDO — Wearable cardioverter defibrillator vests failed to significantly cut the rate of arrhythmic death in at-risk post-MI patients but succeeded in significantly dropping total mortality during a median of 84 days of use in the first randomized trial of nonimplanted defibrillators in such patients.

Post-MI patients with a left ventricular ejection fraction of 35% or less at baseline who wore the wearable cardioverter defibrillator (WCD) had a statistically significant 36% relative risk reduction in total mortality and an absolute total death reduction of 1.7%, compared with controls, in the first randomized trial to test the efficacy of a WCD, Jeffrey Olgin, MD said at the

CARDIOVASCULAR MEDICINE

Wearable defibrillator cuts post-MI mortality

BY MITCHEL L. ZOLER
MDedge News

ORLANDO — Wearable cardioverter defibrillator vests failed to significantly cut the rate of arrhythmic death in at-risk post-MI patients but succeeded in significantly dropping total mortality during a median of 84 days of use in the first randomized trial of nonimplanted defibrillators in such patients.

Post-MI patients with a left ventricular ejection fraction of 35% or less at baseline who wore the wearable cardioverter defibrillator (WCD) had a statistically significant 36% relative risk reduction in total mortality and an absolute total death reduction of 1.7%, compared with controls, in the first randomized trial to test the efficacy of a WCD, Jeffrey Olgin, MD said at the

Continued on following page
annual meeting of the American College of Cardiology.

Despite this overall mortality benefit, the 1,524 patients randomized to the WCD group failed to show a significant improvement in the rate of sudden and ventricular tachycardia death, the primary endpoint for the study, said Dr. Olgin, chief of cardiology at the University of California, San Francisco. Total mortality was a secondary endpoint in the study. Based on the total mortality benefit observed and the “totality of evidence” from prior, uncontrolled observational studies, Dr. Olgin concluded that it is now “reasonable” to protect post-MI patients with ejection fractions of 35%.
or less during the first 40-90 days following an MI when patients can then be assessed for receiving an implantable cardioverter defibrillator. That would be an upgrade from the current American College of Cardiology/American Heart Association guidelines on managing ventricular arrhythmias and preventing sudden cardiac death, issued in 2017, that classified WCDs as a class IIb recommendations – “may be reasonable” – for post-MI patients with a reduced left ventricular ejection fraction (Circulation. 2017 Oct 30;doi:10.1161/CIR.0000000000000549).

WCDs are currently approved for routine prescribing by U.S. physicians, but their use is very variable in post-MI patients. Just before Dr. Olgin delivered his report at the meeting, a poll of the several thousand meeting attendees who heard his talk showed that roughly a third reported routinely prescribing WCDs, with the other two-thirds saying they did not.

Several electrophysiologists who heard the report agreed that further research needs to better tease out which post-MI patients get the most benefit from this treatment.

With a cost for a WCD of about $10,000 for about 3 months of treatment it would be better to target a “subgroup at higher risk,” commented David J. Wilber, MD, professor of medicine and director of the Cardiovascular Institute at Loyola University Medical Center in Maywood, Ill.

The patients enrolled in the study “were not a sick population; they had a low event rate,” commented Sana M. Al-Khatib, MD, professor of medicine at Duke University in Durham, N.C. and chair of the panel that wrote the 2017 ventricular arrhythmia guidelines. She suggested testing the efficacy of WCDs in post-MI patients with lower ejection fractions or those with a greater history of heart disease prior to their index MI. Nearly half of the patients enrolled in the study had New York Heart Association class I symptoms, indicating that they had mild heart disease, she noted in an interview.

Another issue left unresolved by the results Dr. Olgin reported was how much of the mortality benefit was attributable to the shocks delivered by the tested WCDs and how much derived from the arrhythmia monitoring that the WCDs provided. Dr. Al-Khatib suggested a new study to compare the efficacy of WCDs against management directed by use of an implantable loop recorder.

Sana M. Al-Khatib, MD, professor of medicine at Duke University in Durham, N.C. and chair of the panel that wrote the 2017 ventricular arrhythmia guidelines. She suggested testing the efficacy of WCDs in post-MI patients with lower ejection fractions or those with a greater history of heart disease prior to their index MI. Nearly half of the patients enrolled in the study had New York Heart Association class I symptoms, indicating that they had mild heart disease, she noted in an interview.

Another issue left unresolved by the results Dr. Olgin reported was how much of the mortality benefit was attributable to the shocks delivered by the tested WCDs and how much derived from the arrhythmia monitoring that the WCDs provided. Dr. Al-Khatib suggested a new study to compare the efficacy of WCDs against management directed by use of an implantable loop recorder.
Smoking cessation therapy did not up CV events risk

BY AMY KARON
MEdge News

Smoking cessation therapy with transdermal nicotine replacement therapy (NRT), buproprion hydrochloride, or varenicline did not increase the risk of cardiovascular events among stable adult smokers with up to 1 year of follow-up.

“In what we believe to be the largest smoking cessation clinical trial and the only trial comparing NRT, buproprion, and varenicline [with] placebo, we found no signal that smoking cessation pharmacotherapy increases the risk of serious cardiovascular disease or cardiovascular adverse events in a general population of smokers,” concluded Neal L. Benowitz, MD, of the University of California, San Francisco, and his associates. “While the number of events was small, the incidence of serious cardiovascular events was low, suggesting that any absolute increase in risk that we might have missed would be low and not clinically meaningful.” The findings were reported online April 9 in JAMA Internal Medicine.

In this double-blind, multicenter, triple-dummy trial (EAGLES), Dr. Benowitz and his associates randomly assigned 8,058 adult smokers, who did not have acute or unstable cardiovascular disease, to receive buproprion (150 mg twice daily), varenicline (1 mg twice daily), NRT (21-mg/day patch with tapering), or placebo for 12 weeks, followed by 12 weeks of follow-up. A total of 4,595 patients agreed to be followed for another 28 weeks during an extension phase of the trial. More than half of the patients were women and the average age of a participant was 47 years. The primary endpoint was time to major adverse cardiovascular event (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The researchers selected time to MACE as their primary endpoint to better detect differences among groups. One of the secondary end points was the occurrence of MACEs over the same three time intervals. Additionally, cardiovascular deaths, nonfatal MI, and nonfatal stroke (the components of MACE) were evaluated individually, as were hospitalizations for congestive heart failure and serious arrhythmias.

Differences in time to onset of MACE between all four patient groups were not significant. The overall incidence of MACEs was less than 0.5% during all observation periods. There were also no significant differences in rates of the individual types of MACE, coronary revascularization, hospitalization for unstable angina, or new or worsening peripheral vascular disease requiring treatment among groups.

Changes in body weight, blood pressure, and heart rate also were similar across patients.

Consider spironolactone in treatment-resistant hypertension

BY BRUCE JANCIN
MEdge News

ORLANDO – More than one-third of patients with treatment-resistant hypertension in U.S. cardiology practices are eligible for preferential consideration of spironolactone as their fourth-line agent in accord with the practice-changing findings of the PATHWAY-2 trial, Lauren Thompson, MD, said at the annual meeting of the American College of Cardiology.

She presented a study that harnessed the ACC’s National Cardiovascular Data Registry PINNACLE Registry – the largest observational outpatient cardiovascular registry in the world – to assess the potential impact of PATHWAY-2 on the management of treatment-resistant hypertension (TRH) in U.S. cardiology practices. And as she discovered, the potential implications for daily practice are huge.

PATHWAY-2 was a randomized, double-blind, crossover trial involving 314 U.K. patients with TRH despite treatment with maximally tolerated doses of three drugs: a diuretic, an ACE inhibitor or angiotensin receptor blocker, and a calcium channel blocker. Patients were randomized to rotate through 12 weeks of once-daily add-on therapy with spironolactone at 25-50 mg, bisoprolol at 5-10 mg, modified-release doxazosin at 4-8 mg, and placebo. All of the add-ons were similarly well tolerated, but spironolactone proved to be easily the most effective fourth drug for TRH (Lancet. 2015 Nov 21;386[10008]:2059-68).

Dr. Thompson, a cardiology fellow at the University of Colorado, Denver, identified 19,044 patients in the PINNACLE registry for 2013-2014 with TRH, defined as uncontrolled blood pressure despite use of drugs from three antihypertensive classes. Of these patients, 37% met the PATHWAY-2 enrollment criteria by virtue of already being on an ACE inhibitor or angiotensin receptor blocker, a calcium channel blocker, and a thiazide diuretic, but not spironolactone. This is the large subgroup which, on the basis of PATHWAY-2, should receive serious consideration of spironolactone as the fourth drug.

The most widely prescribed antihypertensive agents in PINNACLE registry patients with TRH were beta-blockers, in 87%; ACE inhibitors, in 72%; calcium channel blockers, in 71%; and thiazide diuretics, in 69%. Of note, 27% of patients...
This advertisement is not available for the digital edition.
Triple-antihypertensive pill is effective early therapy

BY MITCHEL L. ZOLER
MDEdge News

ORLANDO – Hypertensive adults started on a triple-drug, single daily pill regimen as either initial or early treatment had a sharply better rate of reaching their goal blood pressure after 6 months, compared with usual-care controls, in a multicenter, randomized trial with 700 patients.

“Early use of a low-dose, three-in-one blood pressure—lowering pill is safe and provides faster and better control of blood pressure compared with usual care,” Ruth Webster, PhD, said at the annual meeting of the American College of Cardiology. The tested polypill contained half the standard doses of the angiotensin receptor blocker telmisartan (20 mg), the calcium channel blocker amlodipine (12.5 mg), and the diuretic chlorothalidone (12.5 mg). After 6 months on this regimen, 70% of patients were at their goal blood pressure, compared with 55% of the control patients, and patients on the polypill had on average a 10/5–mm Hg greater reduction in their blood pressure than did patients on usual care, reported Dr. Webster, head of research programs at the George Institute for Global Health in Sydney. Rates of total and serious adverse events and withdrawals because of adverse events were similar in the two study arms, and both arms also had nearly identical levels of treatment adherence, about 95%.

“No prior trial has evaluated a triple, low-dose pill for initial or early treatment,” she noted.

“This is a home run,” said Karol E. Watson, MD, professor of medicine and director of the Women’s Cardiovascular Health Center at the University of California, Los Angeles. “In the past, clinicians were told to pick one drug and push it as hard as you could and then maybe think about adding a second drug. Experience has shown that this does not increase efficacy, but it does increase adverse events, so current guidelines say start with two drugs. Now they are showing for the first time that you should start with three drugs. That goes with what we know.”

“Triple-drug therapy for the masses makes complete sense,” especially now that the blood pressure goal for most patients is less than 130/80 mm Hg, said William B. White, MD, professor of medicine and chief of hypertension and clinical pharmacology at the University of Connecticut in Farmington. Plus, “compliance is vastly improved when you use a combination-drug pill,” he noted.

The blood pressure targets that Dr. Webster and her associates used were less than 140/90 mm Hg except in patients with diabetes or chronic kidney disease, who had a target of less than 130/80 mm Hg. At the time researchers designed the trial they generally accepted blood pressure target for antihypertensive treatment was less than 140/90 mm Hg, Dr. Webster noted.

She also stressed that she did not believe the three specific drugs selected for the polypill made a difference. “The specific drugs we used were not that important. We would probably get the same result with different drugs. It’s about the strategy of using triple, low-dose therapy,” Dr. Webster suggested. Dr. Watson agreed.

The TRIUMPH (Triple Pill vs. Usual Care Management for Patients with Mild to Moderate Hypertension) study enrolled patients at 11 hospital outpatient clinics in Sri Lanka. The average age of the patients was 56 years. The average blood pressure was 154/90 mm Hg. About 59% of patients were not on any antihypertensive drug at baseline, with the rest on a single drug. The study protocol excluded patients on two or more drugs at entry. Roughly 30% of enrolled patients had diabetes, and 1%-2% had chronic kidney disease. Their target blood pressure on treatment during the study was less than 130/80 mm Hg.

The study’s primary endpoint was the percentage of patients at their goal blood pressure after 6 months. Patients in the triple-drug polypill group achieved their goal blood pressure 23% more often relative to the control, usual-care patients, a statistically significant difference. The between-group difference in achievement of goal blood pressure was apparent by the end of the first 6 weeks in the study. Patients in the control arm generally received either one or two drugs during the study, but often at full dose rather than the half doses used in the triple-drug patients. The study’s design specified that patients in the triple-drug arm who were not at their target blood pressure after 6 weeks could, at the discretion of their treating physician, switch to a second formulation that doubled the dosage of each of the three drugs. Patients in the usual-care arm could have their treatment adjusted after 6 or 12 weeks as long as they continued to receive either one or two drugs. After 6 weeks, 68% of patients in the triple-drug arm and 44% receiving usual care were at their blood pressure goal. After 12 weeks, the percentages at goal were 73% of patients on the triple-drug pill and 47% on usual care.

Dr. Webster hypothesized that the triple-drug, low-dose strategy for initial or early treatment would surpass usual care not only in low- and middle-income countries, like Sri Lanka, but also in high-income, industrialized countries such as the United States.

TRIUMPH received no commercial funding. Dr. Webster had no disclosures. Dr. Watson has been a consultant to Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, and GlaxoSmithKline. Dr. White has been a consultant to Novartis.

Eileen M. Handberg, PhD, is a research professor of medicine and director of the Clinical Trials Program at the University of Florida in Gainesville. She had no relevant disclosures. She made these comments in an interview.

VIEW ON THE NEWS

Triple-drug pill boosts compliance, cuts adverse effects

The TRIUMPH results showed the feasibility and efficacy of achieving good blood pressure control with a single pill containing low doses of three different antihypertensive drugs that are well tolerated and have different mechanisms of action. This strategy avoids the adverse effects from drugs used at their maximum dose.

An attraction of this strategy is how seamless it is for patients. They take a single pill with three drugs, which can enhance compliance and in routine practice can reduce their copay. It’s much easier for patients to take a single pill.

Continued from page 38

with TRH were already on spironolactone.

Audience discussion centered around the uncertainties regarding treatment adherence in patients labeled as having TRH.

“I think sometimes clinicians are afraid to prescribe spironolactone in patients that they think might be nonadherent,” one cardiologist observed.

Dr. Thompson noted that it’s not possible to look at prescription-filling rates in the PINNACLE registry.

“Unfortunately, we can’t exclude white coat hypertension or nonadherence as reasons why patients in PINNACLE end up on multiple antihypertensive medication classes. We can see that a prescription was written, but we have no way to know if it was actually filled or not,” she observed.

Also, since patients in cardiology clinics typically have multiple cardiovascular comorbidities, it’s quite possible that patients with TRH who are on a beta-blocker, for example, might not have received that drug for blood pressure control.

Dr. Thompson’s study was supported by the ACC’s National Cardiovascular Disease Registry. She reported having no financial conflicts of interest.

mzoler@mmedge.com
CRITICAL CARE MEDICINE

Long-term statin use may prevent death in sepsis

BY MICHELE G. SULLIVAN
MDedge News

FROM THE JOURNAL CHEST®•

Long-term statin use appears to decrease sepsis mortality by up to 28%, a large health care database review has determined.

Among almost 53,000 sepsis patients, those who had been taking simvastatin were 28% less likely to die within 30 days of a sepsis admission than were patients not taking a statin. Atorvastatin conferred a similar significant survival benefit, reducing the risk of death by 22%, Chien-Chang Lee, MD and his colleagues wrote in the April issue of the journal CHEST®.

Although the physiological link isn’t completely clear, animal studies suggest the survival benefit may be linked to statins’ ability to improve cardiac function, reduce inflammatory cytokines, and slow down neutrophil infiltration into the lung, wrote Dr. Lee of the National Taiwan University Hospital, Taipei, and colleagues.

The drugs also exert a direct antimicrobial effect, he asserted.

“Of note, simvastatin was shown by several reports to have the most potent antibacterial activity,” targeting both methicillin-resistant and -sensitive Staphylococcus aureus, as well as gram-negative and -positive bacteria.

30- and 90-day mortality in 52,737 patients who developed sepsis; the statins of interest were atorvastatin, simvastatin, and rosuvastatin. Patients had to have been taking the medication for at least 30 days before sepsis onset to be included, and patients taking more than one statin were excluded from the analysis.

Patients were a mean of 69 years old. About half had a lower respiratory infection. The remainder had infections within the abdomen, the biliary or urinary tract, skin, or orthopedic infections. There were no significant differences in comorbidities or in other medications taken among the three groups, the researchers added.

Continued on following page

This advertisement is not available for the digital edition.
Few acutely ill hospitalized patients receive VTE prophylaxis

BY DOUG BRUNK
MEdge News

SAN DIEGO – Among patients hospitalized for acute medical illnesses, the risk of venous thromboembolism (VTE) remained elevated 30–40 days after discharge, results from a large analysis of national data showed.

Moreover, only 7% of at-risk patients received VTE prophylaxis in both the inpatient and outpatient setting.

“The results of this real-world study imply that there is a significantly unmet medical need for effective VTE prophylaxis in both the inpatient and outpatient continuum of care among patients hospitalized for acute medical illnesses,” researchers led by Alpesh Amin, MD, wrote in a poster presented at the biennial summit of the Thrombosis & Hemostasis Societies of North America. According to Dr. Amin, who chairs the department of medicine at the University of California, Irvine, hospitalized patients with acute medical illnesses face an increased risk for VTE during hospital discharge, mainly within 40 days following hospital admission. However, the treatment patterns of VTE prophylaxis in this patient population have not been well studied in the “real-world” setting. In an effort to improve this area of clinical practice, the researchers used the Marketscan database between Jan. 1, 2012, and June 30, 2015, to identify acutely ill hospitalized patients, such as those with heart failure, respiratory diseases, ischemic stroke, cancer, infectious diseases, and rheumatic diseases. The key outcomes of interest were the proportion of patients receiving inpatient and outpatient VTE prophylaxis and the proportion of patients with VTE events during and after the index hospitalization. They used Kaplan-Meier analysis to examine the risk for VTE events after the index inpatient admission.

The mean age of the 17,895 patients was 58 years, 55% were female, and most (77%) were from the Southern area of the United States. Their mean Charlson Comorbidity Index score prior to hospitalization was 2.2. Nearly all hospitals (87%) were urban-based, nonteaching (95%), and large, with 68% having at least 300 beds. Nearly three-quarters of patients (72%) were hospitalized for infectious and respiratory diseases, and the mean length of stay was 5 days.

Dr. Amin and his associates found that 59% of hospitalized patients did not receive any VTE prophylaxis, while only 7% received prophylaxis in both the inpatient and outpatient continuum of care. At the same time, cumulative VTE rates within 40 days of index admission were highest among patients hospitalized for infectious diseases and cancer (3.4% each), followed by those with heart failure (3.1%), respiratory diseases (2%), ischemic stroke (1.5%), and rheumatic diseases (1.3%). The cumulative VTE event rate for the overall study population within 40 days from index hospitalization was nearly 3%, with 60% of VTE events having occurred within 40 days.

The study was funded by Portola Pharmaceuticals. Dr. Amin reported having no financial disclosures.

dbrunk@mdedge.com

VIEW ON THE NEWS

The Taiwan connection – as good as it gets

The statin-sepsis mortality link will probably never be definitively proven, but the study by Lee and colleagues gives us the best data so far on this intriguing connection, Steven Q. Simpson, MD and Joel D. Mermis, MD wrote in an accompanying editorial.

“It is unlikely that prospective randomized trials of statins for prevention of sepsis mortality will ever be undertaken, owing to the sheer number of patients that would require randomization in order to have adequate numbers who actually develop sepsis,” the colleagues wrote. “We believe that the next best thing to randomization and a prospective trial is exactly what the authors have done – identify a cohort, track them through time, even if nonconcurrently, and match cases to controls by propensity matching on important clinical characteristics.”

Nevertheless, the two said, “This brings us to one aspect of the study that leaves open a win-

Dr. Mermis and Dr. Simpson are pulmonologists at the University of Kansas, Kansas City. They made their comments in an editorial published in the April issue of CHEST® (Mermis JD and Simpson SQ. CHEST. 2018 April. doi: 10.1016/j.chest.2017.12.004.)

This advertisement is not available for the digital edition.
This advertisement is not available for the digital edition.
Sepsis versus SIRS blood test shows high sensitivity

A molecular host response assay, called SeptiCyte Lab, holds promise as a tool to distinguish between sepsis and noninfectious systemic inflammation (SIRS), reported researchers in an industry-funded study.

Sepsis is a complex and hard-to-diagnose condition, noted two members of the editorial advisory board of CHEST® Physician in interviews. To make things more complicated, there’s not even a standard definition of sepsis, explained board member Nirmal S. Sharma, MD, of the University of South Florida, Tampa.

"Although newer sepsis definitions have been proposed, all of them have pitfalls and are not used universally. Additionally, the presence of inflammatory response leading to suspicion of sepsis can be due to a new infection or underlying disease processes, thus making it difficult to identify the possible cause," said Dr. Sharma. "Culture-negative cases due to the use of antibiotics prior to suspicion/onset of sepsis can further muddle the picture. Finally, in certain subsets of patients, such as the immunocompromised and elderly, the signs of sepsis may be delayed due to inadequate/dampened immune response, thus making early diagnosis difficult."

Blood testing can provide information about germs that are causing an infection, but "they often take several days, and we need to start the antibiotics before we have those results," added Daniel Ouellette, MD, FCCP, the other board member interviewed.

The SeptiCyte Lab assay, which was approved by the Food and Drug Administration for use in diagnosing sepsis in 2017, was developed to help physicians distinguish sepsis from SIRS in patients during their first day of ICU treatment, noted the authors of the new study in the American Journal of Respiratory and Critical Care Medicine.

This new tool seems to overcome some of the obstacles encountered when other diagnostic methods are used to determine if a patient has sepsis.

Russell R. Miller III, MD, FCCM, and his colleagues performed their SeptiCyte Lab assay on patients’ blood samples; this involved real-time, reverse-transcription, quantitative polymerase chain reaction screening designed to analyze the relative expression levels of four genes. The testing procedure took approximately 6 hours from the draw of the blood sample, according to the study, which was recently published online.

The predictive sensitivity of the test was 0.97 in patients unanimously considered to have sepsis.
CRITICAL CARE MEDICINE

Peanut was the biggest culprit in anaphylaxis
PICU admissions

BY THOMAS R. COLLINS
MDedge News

ORLANDO – Food was found to be the most commonly identified trigger, with peanuts the most prevalent food cause, in what researchers say is the largest comprehensive review of anaphylaxis episodes in North America that led to pediatric intensive care unit stays.

Researchers examined the Virtual Pediatrics Systems database, an international database of pediatric intensive care unit (PICU) information, said Carla M. Davis, MD, a pediatrician at Baylor College of Medicine, Houston. During 2010-2015, there were 1,989 pediatric anaphylaxis admissions to these units in North America, she reported at the joint congress of the American Academy of Allergy, Asthma and Immunology and the World Asthma Organization.

Dr. Davis said the study is intended to give a much-needed broad look at what is causing the most severe cases of child anaphylaxis. “Because anaphylaxis is one of the most severe consequences of allergic disease, we decided that this study needed to be done to see really what the landscape was in the most critically ill children,” she said.

Peanuts accounted for 45% of the food triggers, followed by tree nuts and seeds at 19%, and milk at 10%. Common causes aside from food included drug, blood products, and venom, Dr. Davis said.

Anaphylaxis accounted for 0.3% of all PICU admissions over the 5-year period, researchers found. Dr. Davis said this was “higher than what we anticipated.” The overall mortality rate was 1%, and researchers found that peanuts and dairy were main causes of death of all the food-induced cases.

Anaphylaxis occurred more often in children ages 6-18 years than in kids of other ages and was least common among those aged 2-5 years. Asian children were disproportionately represented among the PICU anaphylaxis patients, but the mortality rate didn’t vary by any demographic factors.

Admissions were most likely to happen in the fall and were more common in the Northeast and Western regions of the United States, Dr. Davis reported. She said the deep look at the causes of these severe cases should help drive home the importance of counseling patients and families about prevention.

“For patients that have had a history of an allergic reaction to food or medication, but specifically food, I think really stressing avoidance measures will be something that will be very helpful, as well as counseling about epinephrine injectors and carrying them is going to help,” she said. “I think having a little more knowledge, pediatricians should be able to counsel and refer to allergists when they don’t feel they have all the necessary skills.”

Dr. Davis reported having financial relationships with the companies Aimmune Therapeutics and DBV Technologies.

*chestphysiciannews@chestnet.org*
This advertisement is not available for the digital edition.
**PRACTICE ECONOMICS**

**MedPAC urges CMS to curb low-value care**

**BY GREGORY TWACHTMAN**
**MDedge News**

WASHINGTON — Prior authorization, clinical decision support, provider education, altered cost sharing, and evidence review can and should be employed to reduce the volume of low-value services.

MedPAC found that about 20% of Virginians, across all payers, received a low-value service in 2014, while 15% of Medicaid patients and 11% of commercially insured patients in Oregon received a low-value service in 2013.

MedPAC found that about 20% of Virginians, across all payers, received a low-value service in 2014, while 15% of Medicaid patients and 11% of commercially insured patients in Oregon received a low-value service in 2013.

MedPAC urges CMS to part of the conversation needs to be about revisiting the coverage after a certain amount of time,

Continued on page 56

**Patients more likely to hide from care than seek care**

**BY RICHARD FRANKI**
**MDedge News**

Some people are more likely to seek medical care, and some people are less likely, but which type is more common? The results of a survey of over 14,000 Medicare beneficiaries suggest that the avoid-care type may be a bit more prevalent.

In the survey, 40% of respondents said that they were more likely to keep it to themselves when they got sick, but 36% visit a physician as soon as they feel bad. Almost 29% reported that they avoid going to a physician, but 25% worry about their own health more than others, the Centers for Medicare & Medicaid Services reported based on the results of the 2015 Medicare Current Beneficiary Survey.

The last two questions on propensity to seek care put the avoid-care type in the minority, albeit a somewhat disturbing one: 11% of Medicare patients responding to a survey said that they had a problem and did not seek a physician and 7% had a prescription they did not fill, the CMS noted.

Race and ethnicity made a big difference for some questions: 59% of Hispanics said that they visit a doctor as soon as they feel bad, compared with 44% of non-Hispanic blacks and 31% of non-Hispanic whites. That same order was seen for “worry about your health more than others” — 54% Hispanic, 38% black, and 19% white — and for “avoid going to the doctor” — 44% Hispanic, 34% black, and 26% white, the CMS reported.

The three groups, which were the only race/ethnicities included in the report, were all around 40% for “when sick, keep it to yourself,” while two of the three were the same for “had a problem and did not seek a doctor” (blacks and Hispanics at 14% and whites at 10%) and for “ever had a prescription you did not fill” (whites and Hispanics at 7% and blacks at 10%), the report said.

The estimates on propensity to seek care did not include Medicare recipients who lived part or all of the year in a long-term care facility, which was about 4% of the Medicare population in 2015. The survey included a total of 14,068 respondents.

**Self-reported indicators of propensity to seek care, 2015**

<table>
<thead>
<tr>
<th>Activity</th>
<th>White (%)</th>
<th>Hispanic (%)</th>
<th>Black (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep it to yourself when sick</td>
<td>42</td>
<td>59</td>
<td>29</td>
</tr>
<tr>
<td>Visit a doctor as soon as you feel bad</td>
<td>36</td>
<td>44</td>
<td>31</td>
</tr>
<tr>
<td>Avoid going to the doctor</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Worry about your health more than others</td>
<td>26</td>
<td>34</td>
<td>32</td>
</tr>
<tr>
<td>Had a problem and did not seek doctor</td>
<td>7</td>
<td>14</td>
<td>10</td>
</tr>
<tr>
<td>Ever had a prescription you did not fill</td>
<td>7</td>
<td>14</td>
<td>10</td>
</tr>
</tbody>
</table>

Note: Based on data from the 2015 Medicare Current Beneficiary Survey.
Source: Centers for Medicare & Medicaid Services
This advertisement is not available for the digital edition.
MAY 2018 • CHEST PHYSICIAN

The Centers for Medicare & Medicaid Services needs to do more to routinely reexamine its coverage decisions, noted MedPAC commission member Kathy Buto.

She recalled a December 2007 CMS proposal to cut back reimbursement for cardiac CT scans to symptomatic patients and to only within the context of an approved clinical trial. Three months later, the agency withdrew the proposed national coverage decision and left it to local carriers to determine whether the procedure would be covered.

Dr. Redberg noted that there was extensive lobbying of local carriers, and within 6 months, despite the lack of evidence, everyone was covering cardiac CT.

“A few years later, CMS tried to walk back the coverage because it was just hemorrhaging money for cardiac CT, but there was no chance because it was a capital investment,” she added. “Even when there are restrictions on coverage, CMS doesn’t enforce them.”

Ms. Buto also raised the issue of how much influence CMS has over Medicare Part D prescription drug plan sponsors’ coverage decision policies, but suggested CMS could play a larger role in that.

Commissioner Amy Bricker, vice
president of supply chain strategy at Express Scripts, St. Louis, suggested that, “We need to do more from a Part D perspective to allow plans to manage drug coverage more aggressively and in line with the commercial space. CMS has handcuffed them,” noting that FDA approval, regardless of value, generally means Medicare coverage.

Commissioner Jack Hoadley, PhD, of Georgetown University in Washington, cautioned that any discussion on these or possibly other tools needs to take into account the needs of those who will legitimately benefit from some of the low-value services so they do not inadvertently prevent access for those patients.

gtwachtman@mdedge.com

“We need to do more from a Part D perspective,” said Amy Bricker.
Doctors call for a pause to rethink MIPS measures

BY GREGORY TWACHTMAN
MDedge News

A “time-out” is needed to re-evaluate how quality measures are used as part of Medicare’s Merit-Based Incentive Payment System (MIPS), according to officials at the American College of Physicians. The call comes in the wake of an analysis of MIPS quality measures that found a majority are not valid for ambulatory care internal medicine, according to ACP criteria. Of the 86 MIPS quality measures considered relevant to ambulatory general interest medicine, 37% (32) were rated as valid, 35% (30) were rated as invalid, and 28% (24) were rated as of uncertain validity, Catherine H. MacLean, MD, and her colleagues on the ACP Performance Measurement Committee wrote in a perspective published April 18 in the New England Journal of Medicine.

The quality measures were assessed regarding importance, appropriate care, clinical evidence base, measure specifications, and measure feasibility and applicability. “We also determined that the proportion of the measures that had been developed by the National Committee for Quality Assurance [NCQA] or endorsed by the National Quality Forum [NQF] that were rated as valid by our method,” Dr. MacLean and colleagues wrote. “As compared with measures that were not endorsed by these organizations, greater percentages of NCQA-developed and NQF-endorsed measures were deemed valid [59% and 48%, respectively, vs. 27% for nonendorsed measures], and smaller percentages were deemed not valid [7% and 22% vs. 49% for nonendorsed measures].”

The lack of measures that were found to be valid for primary care is frustrating for doctors and could cause harm to patients, according to the authors. “We need a time-out during which to assess and revise our approach to physician performance measurement.”

The ACP recommends that “physicians with expertise in clinical medicine and research develop measures using clinically relevant methodology,” President Jack Ende, MD, said in a statement. “Performance measures should be fully integrated into care delivery so they can help address the most pressing performance gaps and direct quality improvement.”

The time-out call comes amidst differing opinions on how to proceed with the MIPS track. The Medicare Payment Advisory Commission has recommended to Congress that MIPS be repealed and replaced, while health care experts and physician associations believe the program should stay the course.

As Editor-in-Chief of CHEST® Physician, one of my missions is to better utilize this publication to facilitate communications between CHEST membership and CHEST leadership. This will be the first of a new quarterly column intended to keep our members apprised of Board activities that are of key organizational importance or may simply be of interest.

In 2017, CHEST President John Studdard commissioned a task force to look at the process by which College and Foundation leadership are selected, developed, and assessed. This was partly spurred on by a desire to ensure that we were engaged in best practices, but also an effort to improve the diversity of our leadership profile. After meeting several times through the fall and winter, and looking at practices of both our sister societies and medical societies in other specialties, the task force presented their plan for the creation of a new Governance Committee to both the Board of Regents and the Board of Trustees at the February board meetings.

This committee will be chaired by the Past Presidents of the Board of Regents and the Board of Trustees, and composed of an additional five individuals selected from current members of the Boards. First and foremost, the duty of this new body will be to ensure the overall health and performance of our Boards, by providing ongoing assessment of and feedback about members of our leadership. In addition, the Governance Committee will identify potential gaps in the make-up of our leadership, with a focus on diversity and inclusiveness, and will use those findings in interviewing and selecting both future Board members and new Presidents. Lastly, the committee will regularly review organizational bylaws and committee structures and will propose any recommended changes to the Board of Regents for review and formal vote.

The presentation of this proposal was met with one of the most robust discussions that this writer has seen in his 4 years on the Board of Regents. This would represent a significant change in how CHEST selects its leadership; it would result in a sunsetting of the Nominating Committees of both boards, which had previously taken lead on the selection of Board members and Presidents.

This is an important difference, as the College Nominating committee had included representation from both the Council of NetWorks and the Council of Global Governors, which ensured that a broad swath of our membership had a voice in selecting its leaders.

That noted, many current Board members previously served on these Councils, and so judicious selection of Governance Committee members could continue to ensure broad representation in the selection of our leaders. Another important point is that the process by which members are nominated for leadership positions would not change with this proposal, we would simply have a new body of voters that would select from this group of nominees.

At the end of the discussion, the Board voted to move forward with the formation of the Governance Committee, with an additional commitment to track its success in achieving its goals of improving the function and diversity of CHEST leadership on a regular basis.
Expanding CHEST’s ‘Women in Pulmonary’ Program

The gender gap exists for women in pulmonary medicine. According to the Medscape Pulmonologist Compensation Report 2017, women pulmonologists earned 23% less than their male counterparts even though:

- 2% of women pulmonologists work part time vs 8% of men;
- more women (66%) than men (48%) reported seeking promotion. (Grisham, 2017)

If we take a look at a recent report done by Doximity that analyzed responses on more than 65,000 licensed US doctors across the country, the report reveals that the gap between female and male physicians across the nation, women on average make about $91,000 less annually (Doximity, 2018).

Despite ever-growing enrollment rates for women in medical schools, female physicians are often under-represented in academic and research settings. According to a study published in the Journal of National Medical Association, “between 80 and 90 percent of leadership roles in medicine, like medical school deans, are filled by men.” (Morton & Sonnad, 2007)

These astounding gaps do not stop at the clinician’s door. This gender inequality is evident in the women who are receiving medical treatment, as well. There are two major issues that exist for women seeking treatment:

1. Not being taken as seriously as male patients:
- Women are more likely to be prescribed sedatives for their pain, and men are more likely to be prescribed pain medication. (L. Calderone, 1990)
- Women are more likely to be treated less aggressively in their initial encounters with the health-care system until they prove that they are as sick as male patients with similar symptoms. (Hoffmann & Tarzian, 2001)
- Nationwide, men wait an average of 49 minutes before receiving an analgesic for acute abdominal pain. Women wait an average of 65 minutes for the same thing. (Chen, et al., 2008)
- Multiple studies have shown that female patients’ symptoms are less likely to be taken seriously by doctors, and women are more likely to be misdiagnosed, have their symptoms go unrecognized, or be told what they’re experiencing is psychosomatic. (Hoffmann & Tarzian, 2001) (Carniol, Iwarzon, Jensen-Urstad, Gadler, & Insulander, 2017)

2. Being diagnosed and treated the same as male patients:
- Up until 1993 when the National Institutes of Health Revitalization Act mandated that all women and minorities be included in clinical trials funded by the NIH, the guidelines and diagnosis for treatment have historically been based off the archetypal patient: a 154-pound white male. Because of this, women are often misdiagnosed or receive treatments that are ineffective or potentially harmful to their health. Even still, researchers frequently do not enroll an adequate number of women or fail to analyze or report data separately by sex. (MHC Center, 2014)
- Women and men metabolize drugs differently, yet dosages are rarely broken down by sex. Women also experience different side effects and derive different benefits from the same treatments. (SOLDIN & Mattison, 2009)
- Female patients have a 1.5 to 1.7 times higher chance of having an adverse drug reaction. (Rademaker, 2001)
- There are many diseases and conditions that are alarmingly more prevalent among women. Non-smoking women are three times more likely to get lung cancer than nonsmoking men, according to a comprehensive 2014 report by Brigham and Women’s Hospital in Boston, called “Women’s Health Can’t Wait.” (MHC Center, 2014)

“While the number of women participating in lung cancer clinical trials has risen, women—particularly those from racial and ethnic minorities—are still less likely to enroll in these trials than men. Even when studies include women, researchers often fail to analyze data by sex or include hormone status or other gender-specific factors, making it difficult to uncover differences in incidence, prevalence, and survivability between men and women and to replicate the studies.” (MHC Center, 2014)

In the pulmonary space, there is growing evidence that a number of pulmonary diseases affect women differently and with a greater degree of severity than men. Respiratory conditions that impact women nearly exclusively include pulmonary hypertension, catamenial diseases, and pregnancy-associated asthma exacerbation. (Pinkerton, et al., 2015)

2015;192(1):11-16.

According to the CDC, cancer is the number one cause of death for women ages 35-64, and the number one cancer killer in women is lung cancer. Women have been taught to care and take notice of the symptoms of breast cancer, HPV, ovarian cancer, and other “women’s diseases,” and yet, more women die every day from lung cancer than from breast, ovarian, and uterine cancers combined.

Why CHEST?
Now, why does this matter to us at CHEST? What can we do about it? How do we begin to tackle such a large issue that permeates nearly every facet of society?

CHEST is in a unique position to not only address the professional development needs of our female membership, but with the help and leadership of the CHEST Foundation and a new partnership with HealthyWomen, we are poised to address the gaps in education for our clinicians, patients, and the public.

To address these needs, the Women in Pulmonary program was created. Women in Pulmonary started as a yearly luncheon and has expanded into a yearlong program that will work to fill these gaps by not only elevating the wants and needs of women in pulmonary medicine, but also by bringing awareness to clinicians, patients, and the public on key information to changing how women are viewed in medicine and how diseases are perceived across genders.

Bibliography
Calderone KE. The influence of gender on the frequency of pain and sedative medication administered to postoperative patients. Sex Roles. 1996;33(11-12):713-725.
MHC Center. Sex-Specific Medical Research: Why Women’s Health Can’t Wait. Brigham and Women’s Hospital, Mary Horrigan Connors Center for Women’s Health & Gender Biology. Brigham and Women’s Hospital;2014.
One of the best ways to stay connected with CHEST and up-to-date on the latest news and research is through our social channels. Twitter is a social platform that is constantly growing for the organization. Since 2009, we’ve had the opportunity to connect with over 20,000 individuals and impact millions with just a simple tweet or sharing of information. As a means to inform our highly active audience and bring the conversation to a social space, we’ve utilized the platform to help drive the conversation on various topics. CHEST moderates a public conversation via Twitter (@accpchest) around topics in pulmonary, critical care, and sleep medicine every few weeks.

So, what exactly is a Twitter chat? Twitter chats are conversations that are held on the social platform and linked together by a distinct hashtag. We typically use the hashtag #pulmCC (which stands for pulmonary, critical care) and allow individuals from all across the globe to join in on the conversation and share their input. In addition to being a great networking opportunity, our chat recently began offering MOC points to CHEST members who attend Twitter chats and are eligible to receive participation points. We recently began offering CME credit for some of our chats, as well.

Over the last 6 years, we’ve hosted a wide range of Twitter chat topics, ranging from asthma to lung cancer. Some of those chats focused on the following topics:

- The Best of 2017: Highlights, Advancements, New Science
- Improving Lung Health Through Pulmonary Rehabilitation
- Caring for the Caregiver: Vulnerability and Burnout
- What Trainees Need to Know About Pulmonary, Critical Care & Sleep
- #VTEonSoMe Twitter Chat—Let’s Talk Blood Clots! Surgeries, Birth Control, and 40

This past March, we held our Twitter chat Sepsis: Revisions, Advancements, New Therapies, led by Drs. Chris Carroll, Alex Niven, and Steven Q. Simpson. We had over 4.2 million impressions!

Every Twitter chat serves a different purpose, typically based on the topic and the individuals we believe would be most interested in the topic. These chats help us spark conversations on the latest research, advancements, and potential opportunities within the pulmonary/critical care field. They also provide physicians with a great opportunity to network and get acquainted with the #pulmCC community.
COPD-OSA overlap syndrome

BY WALTER T. MCNICHOLAS, MD, FCCP

Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) each affect at least 10% of the general adult population and, thus, both disorders together, commonly referred to as the overlap syndrome, could be expected in at least 1% of adults by chance alone. However, there is evidence of important interactions between...
the disorders that influence the prevalence of the overlap, which have implications for the development of comorbidities, and also for management (McNicholas WT. Chest. 2017; 152[6]:1318). Furthermore, sleep quality is typically poor in COPD, which has been linked to worse pulmonary function and lung hyperinflation and may contribute to daytime fatigue.

**Interactions between COPD and OSA that may influence the prevalence of overlap**

Previous reports have presented conflicting results regarding the likely association between COPD and OSA, which may partly reflect different definitions of OSA, patient populations, and methodologies of investigation. However, COPD represents a spectrum of clinical phenotypes ranging from the hyperinflated patient with low BMI (predominant emphysema phenotype) to the patient with higher BMI and tendency to right-sided heart failure (predominant chronic bronchitis phenotype). The predominant emphysema phenotype may predispose to a lower likelihood of OSA, and there is recent evidence that lung hyperinflation is protective against the development of OSA by lowering the critical closing pressure of the upper airway during sleep. Furthermore, the degree of emphysema and gas trapping on CT scan of the thorax correlates inversely with apnea-hypopnia index in patients with severe COPD (Krachman SL et al. Ann Am Thorac Soc. 2016;13[7]:1129).

In contrast, the predominant chronic bronchitis phenotype predisposes to a higher likelihood of OSA because of higher BMI and likelihood of right-sided heart failure. Peripheral fluid retention in such patients predisposes to OSA because of the rostral fluid shift that occurs during sleep in the supine position, predisposing to upper airway obstruction by airway narrowing. The COPDGene study reports that the chronic bronchitis phenotype has a higher prevalence of OSA even in the absence of differences in BMI and lung function (Kim V et al. Chest. 2011;140[3]:626). Upper airway inflammation associated with cigarette smoking may also contribute to the development of OSA, and corticosteroid therapy may adversely affect upper airway muscle function. OSA also appears to exacerbate lower airway inflammation in COPD. In practice, most patients with COPD have a mixture of emphysema and chronic bronchitis, and the probability of OSA will represent the balance of these protective and promoting factors in individual patients (Fig 1).

While there is evidence of increased mortality in patients with COPD and OSA alone, a recent report based on the Sleep Heart Health Study somewhat surprisingly found that the incremental contribution of declining lung function to mortality diminished with increasing severity of SDB measured by AHI (Putcha N et al. Am J Respir Crit Care Med. 2016;194[8]:1007). Thus, the epidemiologic relationship of COPD and OSA and related clinical outcomes remains an important research topic comparing different clinical phenotypes.

**Mechanisms of interaction in the overlap syndrome and implications for comorbidity**

COPD and OSA are associated with...
Update: FDA workshop on medical devices for SDB

Dr. Neil Freedman and Barbara Phillips represented CHEST at an FDA workshop on April 16 on “Study Design Considerations for Devices Including Digital Health Technologies for Sleep Disordered Breathing (SDB) in Adults. The other organizational participants were The American Academy of Dental Sleep Medicine; The American Academy of Neurology; The American Academy of Sleep Medicine; and The American Sleep Apnea Association. Here are the questions that the FDA asked the panelists:

1. FDA is seeking to promote innovation and expedite the clinical development of devices intended for the diagnosis and treatment of sleep disordered breathing (SDB). How should the following conditions (including their severity, eg, mild, moderate, severe, if appropriate) be defined for the purpose of creating appropriate inclusion/exclusion criteria for a clinical study for SDB devices?
   a. Apnea
   b. Hypopnea
   c. Sleep Disordered Breathing (SDB)
   d. Obstructive Sleep Apnea Syndrome (OSAS)
   e. Central Sleep Apnea Syndrome (CSAS)
   f. Primary Snoring

2. Polysomnography (PSG) has been widely accepted as the “gold standard” test for the diagnosis of OSA and primary snoring. However, home sleep apnea testing (HSAT) has emerged in recent years as an alternative or complementary diagnostic tool for SDB.
   a. Can HSAT be used for establishing a baseline diagnosis and for the collection of clinical performance data for device trials for OSA, CSA, or primary snoring? If so, what are the recommended parameters that should be collected by an HSAT (eg, nasal pressure, oximetry, chest and abdominal respiratory inductance plethysmography)?
   b. What constitutes a technically adequate test (either PSG or HSAT, if appropriate) for establishing a baseline diagnosis of SDB for device studies (eg, number of hours, number of nights)?

3. FDA has received an increasing number of pre-market applications for devices intended to treat SDB. How should studies for the various technologies (eg, intra-oral appliances, externally worn devices, electrosurgical devices for tissue reduction, and passive or active implantable devices of the upper airway) be designed with respect to the following factors (please consider whether your recommendations would vary if the device was an implant vs an externally worn device):
   a. What is the most appropriate control group (eg, comparison to baseline measures, randomization to a concurrent control group)?
   b. What is the minimum duration of the study? For implants and surgical procedures, how long after the intervention should the effectiveness endpoint be assessed?
   c. What objective parameter or combination of parameters should be used for the primary effectiveness endpoints (eg, AHI, ODI, T90, or other non-PSG/HSAT parameters)?
   d. What would be a clinically meaningful difference for the above primary effectiveness endpoint(s) between/among study arms or within a study arm?

4. What patient-reported outcomes (PROs) are appropriate in the evaluation of SDB devices?
   a. What factors are important in developing a reference database (eg, demographics, validation)?
   b. What are the important safety and effectiveness concerns for SDB digital health devices used in the following settings:
      i. A physician office or sleep center environment?
      ii. A nonclinical environment?
      iii. Prescription vs OTC use?

There was significant discussion and quite a bit of controversy. Among the recommendations to the FDA were that home testing is adequate and acceptable for clinical trials, that the ODI4 is more predictive and reliable than the AHI, and that the syndrome of OSAHS includes symptoms, one of the most important of which is sleepiness. It was acknowledged that digital health devices have the potential to greatly increase access to diagnosis, but access to treatment will need to be addressed, as well. I think this was a very important meeting, and the outcome will likely impact our members. The ultimate goal is to publish a paper about recommended techniques, outcomes, and inclusion characteristics/definitions to be used in clinical trials for new devices to diagnose or treat sleep apnea.
This advertisement is not available for the digital edition.
Impacting careers, impacting patient care

Thank you for all you do to champion lung health. Your donation supports projects, such as grant funding, which are boosting patient outcomes, improving community health, and advancing the research that continues to enhance the journey for those facing pulmonary illnesses. Each year, your generosity funds more than $550,000 in clinical research and community service grants, allowing CHEST members to develop and implement their ideas through securing preliminary data support, distinguishing themselves among their colleagues, and advancing chest medicine toward medical breakthroughs.

One such story of the advancements being made in communities around the world begins in New York City. Kids in urban settings are disproportionately affected by asthma. Although we know that being active is good for respiratory health, in an urban setting, children may be breathing in more pollutants. In inner city neighborhoods playgrounds are often next to major highways or industrial areas. These recreational areas may be increasing the risk of developing pulmonary diseases. This is a prime example of why researchers like Dr. Stephanie Lovinsky-Desir are working to find a solution to champion lung health.

Dr. Lovinsky-Desir is a pediatric pulmonologist based at Columbia University and the recipient of the CHEST Diversity and Young Investigator Award in 2014 for her project on Urban Tree Canopy Exposure, DNA Methylation, and Allergies in Pediatric Asthma. The grant helped launch her research. “It’s success has resulted from it. The findings she concluded from her CHEST diversity grant research allowed her to modify her study and receive the following awards: an award through her institution, the National Institute of Health K22 award, multiple awards including an NIH K01, a children’s scholar award, and the Harold Amos Medical Faculty Development Award. Stephanie is excited for her future research after recently receiving a very competitive score from her NIH. She believes the CHEST Foundation award jump started her research career, and these other successes have resulted from it. “It’s more than a research project. We are building a research program.” Her current research involves exploring epigenetic mechanisms, particularly DNA methylation, in pediatric and adult allergic asthmatics, as well as understanding the effects of environmental pollutants on asthma, activity, and obesity. Though Dr. Lovinsky’s career as a researcher grew from the foundation grant, she says, “The benefit of this award specifically was the gateway to the CHEST Foundation and all of the other opportunities within CHEST.” She is actively involved in the Diversity and Inclusion Task Force and brings many ideas to the table for the future of the CHEST Foundation. “I am committed to being involved with CHEST because of how much the organization has impacted my career. I enjoy giving back by participating in the task force.” Her clinical research and involvement in CHEST demonstrates the direct impact your generous
support has on physicians, patients, and lung health.

Thank you for making important research like this possible. Your generosity is the catalyst for change in a world where lung diseases are ranking as one of the top causes of death for men and women everywhere. You’re improving patient outcomes every day, and we thank you from the bottom of our hearts.

Your continued support will make it possible for the next generation of researchers to launch their careers. You can be a Champion for Lung Health and DONATE today through a new gift to the CHEST Foundation. We can meet our goals for the health professionals, patients, and caregivers we serve with your much appreciated and essential support.

To donate:
Web: chestfoundation.org/donate
Phone: 224/521-9527

Again, thank you for all you do to improve patient outcomes. You are the lung health champions that patients and families count on to positively impact lung health.

Lisa K. Moores, MD, FCCP
President & Trustee

Mike E. Nelson, MD, FCCP
Immediate Past President & Trustee

AACN Update

AACN releases expert consensus statement on teleICU nursing practice

To remain at the forefront of expanding evidence-based practices in all aspects of critical care, facilities must include teleICUs.

In 2013, the American Association of Critical-Care Nurses (AACN) first defined standards for the emerging telernursing practice in the ICU and has recently published an update, AACN TeleICU Nursing Practice: An Expert Consensus Statement Supporting High Acuity, Progressive and Critical Care.

The new consensus statement, which creates a framework for implementing, evaluating, and improving teleICU nursing practice, addresses the new findings in this fast-growing area of health care. It also establishes a model for achieving excellence and optimal patient care outcomes through the following:

- Shared knowledge and goals
- Mutual respect
- Skilled communication
- True collaboration
- Authentic leadership
- Optimized technology
- Practice excellence

A 12-person task force, including teleICU nurse leaders, contributed to the statement and brought a fresh perspective to this area of practice.

Task force co-chair Pat Herr, clinical integration director of eCare ICU at Avera Health, says it was important to harness the energy and lessons learned from experienced teleICU leaders.

“TeleICUs continue to evolve to meet the needs of patients and health systems,” Herr adds. “New technology options and new partnership models are available, and nurse leaders play an important part in using these tools to improve patient care.”

The earliest teleICU design concepts employed a physician-only model of care, but it quickly became clear that critical-care nursing was a necessary component. Today, the most effective teleICU models implement collaborative care that includes physicians, nurses, information technology, and administrative support personnel.

Opportunities in teleICU are one way to retain knowledgeable nurses, who can bridge clinical expertise gaps and provide an additional layer of skilled critical care. TeleICU care ensures delivery of both optimal patient outcomes and timely knowledge to support physicians, nurses, and the entire bedside care team.

Task force member Lisa-Mae Williams, operations director of telehealth and eICU at Baptist Medical Center, says she learned from experienced teleICU leaders.

It was important to harness the energy and lessons learned from experienced teleICU leaders.

“The earliest teleICU design concepts employed a physician-only model of care, but it quickly became clear that critical-care nursing was a necessary component. Today, the most effective teleICU models implement collaborative care that includes physicians, nurses, information technology, and administrative support personnel. Opportunities in teleICU are one way to retain knowledgeable nurses, who can bridge clinical expertise gaps and provide an additional layer of skilled critical care. TeleICU care ensures delivery of both optimal patient outcomes and timely knowledge to support physicians, nurses, and the entire bedside care team.”

Task force member Lisa-Mae Williams, operations director of telehealth and eICU at Baptist Medical Center, says she learned from experienced teleICU leaders.

“A new date has been announced for CHEST 2018, the premier education event in clinical chest medicine. CHEST 2018 has a new date: October 6-10. Join us in San Antonio, Texas, for CHEST 2018, the premier education event in clinical chest medicine. This year’s Learn by Doing-focused program is built by expert faculty, and includes cutting-edge educational sessions and hands-on opportunities designed with the goal of learning through active participation.

Learn More and Register Now | chestmeeting.chestnet.org

Complete Details | chestnet.org/live-learning

NEW for 2018

Lung Cancer: A Multidisciplinary Course for Pulmonologists Covering Current Paradigms for Diagnosis and Management

Attend to:
- Discuss the current multidiscipline knowledge base regarding lung cancer diagnosis options for patients with early and late-stage lung cancer.
- Develop hands-on skills directed toward physiologic evaluation of patients with lung cancer, BRCA, navigational bronchoscopy, pleural catheters, and malignant effusion pleurodesis.
- Capture new ideas on how to optimize the multidisciplinary conference approach to outstanding lung cancer care.
- Interpret multidisciplinary images in the care of patients with lung cancer, and utilize newer tumor markers for oncologic planning.
- Optimize your interdisciplinary skills with regards to lung cancer diagnosis, therapy, and patient care.

Learn More and Register Now | chestmeeting.chestnet.org

OCTOBER 6-10

CHEST 2018

SAN ANTONIO • OCTOBER 6-10

Join us in San Antonio, Texas, for CHEST 2018, the premier education event in clinical chest medicine.

MDEDGE.COM/CHESTPHYSICIAN • MAY 2018 • 71
San Antonio hotels for CHEST 2018

Are you ready for CHEST Annual Meeting 2018? Get ready with exclusive hotel deals for your trip to San Antonio from onPeak, the official hotel provider for CHEST 2018. Through onPeak, we are able to bring you the lowest rates, best hotels, and great amenities for your trip all along the beautiful San Antonio River Walk. onPeak also provides flexible booking policies, great group tools, and a full team of wonderful customer service agents to ensure you have a smooth booking process.

Hotel Contessa
Step into the marble lobby accented with glass sconces and towering palm trees and you’ll know you’ve made the right choice on where to stay. The ambience of this 265 all-suite property with heated rooftop pool, full-service spa, gourmet restaurant, and modern meeting space is unmatched by any other downtown hotel. Our dedicated service team is devoted to making any stay – leisure or business – a memorable experience. The Hotel Contessa extends to her guests a relaxing respite in an urban setting coupled with all the amenities of a large resort.

Hyatt Regency San Antonio
Experience the heart of the River Walk at Hyatt Regency San Antonio. This is the only hotel on the River Walk directly overlooking the historic Alamo, connecting two of San Antonio’s top destinations through the 16-story atrium lobby. This four-diamond hotel includes contemporary guest rooms, a rooftop pool, Stay-Fit gym, and a relaxing spa. The experienced staff adds a genuine touch to world-class amenities.

Marriott Riverwalk
The San Antonio Marriott Riverwalk hotel charmingly captures the vibrant culture and style of this romantic city, welcoming you and ensuring an enchanting stay. This hotel is located in the heart of downtown San Antonio, offering sweeping balcony views of the fabulous River Walk district. The 303-room hotel invites guests into a contemporary lobby with Texas flair: chilied walls, dark-wood trim, and wrought-iron accents. Explore the history, culture, and culinary delights along the River Walk.

Del Rio offers superior service, extensive guest amenities, and is the only hotel in downtown San Antonio that features a private balcony in every room. Tex’s Riverwalk Sports Bar & Grill, Durty Nelley’s Irish Pub, Ibarra Riverwalk Patio Restaurant & Bar, and the Rincon Allegre Lobby Bar await to satisfy individual tastes.

Hotel information provided by onPeak.

Westin Riverwalk Hotel
The Westin Riverwalk Hotel boasts 473 rooms and luxury suites with Texan hospitality and warm residential style. This riverfront hotel is the perfect location to relax and recharge. Expect a warm welcome when you visit the best of San Antonio River Walk hotels. Enjoy delicious dark chocolates imported from Venezuela when you check in and amenities such as The Westin Heavenly Bed* and Heavenly Bath* products that will leave you feeling refreshed and rejuvenated. The hotel rooms also include sparkling city or river views and elegant, oversized marble bathrooms with pampering bath amenities.

Don’t forget to book your hotel before they sell out! View the official hotel block at http://onpeak.com/CHEST-2018.

Note that onPeak is the only official hotel provider associated with our event. While other hotel resellers may contact you offering accommodations for your trip, they are not endorsed by or affiliated with the meeting. Beware that entering into financial agreements with unendorsed companies can have costly consequences.

Hotel information provided by onPeak.

Continued from previous page

Health South Florida, says telemedicine doesn’t mean fewer jobs for bedside nurses; it’s an extra set of eyes to surveil vital signs and support a clinical workforce that may be stretched thin.

“At the bedside, when teleICU came to my unit, I was very skeptical,” Williams recalls. “But after seeing for myself what those extra nurses brought to the table – the available technology and time they had to assess trends and really delve into what’s going on – it turned out to be the best tool to care for our patients.”

In addition to knowledge gaps, nurse turnover is on the rise, according to the “2017 Survey of Registered Nurses: Viewpoints on Leadership, Nursing, Shortages and Their Profession” from AMN Healthcare, San Diego. The survey also finds that more than one in four nurses plan to retire within a year, and 73% of baby boomers expect to retire in 3 years or less.

The shortfall is already more pronounced in rural hospitals facing staffing challenges and in specialty areas where additional education, training, and experience are critical to improve patient safety and outcomes.

The expertise and dynamic, front-line viewpoint of teleICU experts has resulted in a comprehensive, patient-centric update. Their experience delivering both bedside and remote care was instrumental in developing valuable clinical scenarios. The scenarios in the statement are genuine examples of how each key recommendation is implemented by physicians and bedside and teleICU nurses to provide continuity of care; identify high-risk patients; and decrease mortality rates by filling gaps in monitoring and staff expertise.

As a leader in the delivery of evidence-based practices, AACN offers CCRN-E specialty certification for nurses who primarily provide acute or critical care for adult patients in a teleICU setting, which is connected to the bedside via audiovisual communication and computer systems. Visit www.aacn.org > Certification > Get Certified > CCRN-E Adult to learn more.

The expert consensus statement is available for AACN members to download or to purchase a hard copy.

References
Yale School of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, is seeking candidates to be members of our Pulmonary Vascular Disease (PVD) Center. This academic position will be filled at a rank of: Instructor, Assistant Professor, Associate Professor with qualifications. Experienced candidates who have a specific career interest in advancing PVD research and clinical programs are encouraged to apply. Candidates are expected to have outstanding skills in the clinical and educational arena and will have the opportunity to take an active role teaching and mentoring fellows and residents in clinical & translational research. Successful applicants are expected to make a significant contribution to the clinical, educational, and research missions of the section. The PVD Center at Yale is rapidly expanding clinically, is accredited by the Pulmonary Hypertension Association as a Comprehensive Care Center, and is involved in basic science, translational, and clinical research. The candidates are expected to evaluate and manage all groups of pulmonary hypertension, and should have experience in all forms of PAH management, including oral, inhaled, and infused therapies. Research experience and proven productivity are an advantage. Minimum requirements include: board certification in pulmonary diseases and critical care medicine. All application materials should be submitted electronically to: http://apply.interfolio.com/46514

Review of applications will begin immediately, and will continue until the position is filled.

Yale University is an affirmative action/equal opportunity employer and welcomes applications from women, persons with disabilities, protected veterans and members of minority groups.
Interventional Chest/Diagnostic Procedures
Review of The AMPLE Trial: is talc making a comeback?
A proposed advantage of indwelling pleural catheters (IPC) is their purported ability to reduce hospitalization time when compared with the more traditional talc pleurodesis procedure. The recently published AMPLE trial was a multicenter randomized trial comparing the impact of IPCs vs talc pleurodesis on hospitalization days in patients with malignant pleural effusions. One-hundred forty-six patients were randomized for pleurodesis to either IPC vs pleurodesis via talc slurry in nine centers in Australia, New Zealand, Singapore, and Hong Kong. Patients were followed for up to 12 months. Secondary outcomes included need for further pleural intervention, breathlessness, quality of life, and adverse events.

Patients randomized to IPC spent on average 2 days less in the hospital (10 vs 12 days), a difference that was statistically significant, though of questionable clinical relevance, and somewhat disappointing in terms of questionable clinical relevance, and significant morbidity. Most patients receive systemic corticosteroids during acute asthma exacerbations. The most recent Global Initiative for Asthma (GINA) guidelines recommend increasing ICS at the first signs of an asthma exacerbation in an effort to lessen the need for systemic corticosteroids (GINA. Global strategy for asthma management and prevention. 2017. http://www.ginasthma.org/).

In a recent issue of the New England Journal of Medicine, Jackson and colleagues at the National Heart, Lung, and Blood Institute AsthmaNet published the results of a randomized, double-blind 48-week trial, which included 254 children between ages 5 and 11 years with mild-moderate asthma. Their objectives were to compare exacerbation rates, time to first exacerbation, acute care visits, and bronchodilator use in children randomized to treatment with either high (5 x baseline ICS dose x 7 days) or low dose inhaled corticosteroids early in a drop to the “yellow zone” (Jackson, et al. N Engl J Med. 2018;378[10]:891). Time to asthma exacerbations and exacerbations that required treatment with corticosteroids did not significantly differ between the low dose and high dose groups. Unexpectedly, the rate of exacerbations was higher with the high dose compared with the low dose group (0.48 vs 0.37). The children who were in the high dose group received 16% more ICS compared with the low dose group. Although not significant, there was a lower linear growth rate, ~0.23 cm per year seen in this high-dose group than in the low-dose group. Additionally, the use of bronchodilator, symptoms, and the rates of evaluation by a physician (ie, emergency department or urgent care visits) did not significantly differ between the two groups.

This study was specific to school-age children with mild-moderate persistent asthma treated with low dose ICS with a history of good adherence. Overall, this well-designed study helps address a question that many clinicians have regarding escalating ICS in the “yellow zone.” Escalating ICS did not reduce exacerbations at the cost of a lower linear growth rate. When it comes to escalating ICS for asthma exacerbation, more is not better.

In conclusion, in children with mild-to-moderate persistent asthma treated with daily inhaled ICS, ESCG guidelines recommend increasing ICS at the first signs of an asthma exacerbation in an effort to lessen the need for systemic corticosteroids (GINA. Global strategy for asthma management and prevention. 2017. http://www.ginasthma.org/).

This Month in the Journal CHEST®

Editor’s Picks

GEANTS IN CHEST MEDICINE
Sonia Buist, MBChB. By Dr. J.A. Krishnan.

EDITORIAL
Is Big Tobacco Still Trying to Deceive the Public? This Is No Time to Rest on Our Laurels. By Drs. D. R. McCaffree and N. R. Desai.

ORIGINAL RESEARCH

Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review. By Dr. A. C. Lajoie, et al.

Tai Chi and Pulmonary Rehabilitation Compared for Treatment-Naive Patients With COPD: A Randomized Controlled Trial. By Dr. M. I. Polkey, et al.

INDEX OF ADVERTISERS

Actelion Pharmaceuticals US, Inc. Corporate 41

Allergan AVYCZ 30-33

AstraZeneca BEVESPI AEROSPHERE 26-29

EKOS Corporation Corporate 76

Genentech USA, Inc. Ebitet 2-5

Gilead Sciences, Inc. Letairis 61-63

GSK group of companies BREO 9

NUCALA 20-23

TRELEGY 43-50

Pfizer Inc. Ruvatio 11-13

Sanofi and Regeneron Pharmaceuticals, Inc. Corporate 39

Sunovion Pharmaceuticals Inc. LONGHALA MAGNAR 16-18

UTILBIRON NEOHALER 34-37

SEEBRE 56-58

“CHEST” *CHEST®
Pulmonary Physiology, Function, and Rehabilitation Understanding cardiopulmonary exercise testing

The cardiopulmonary exercise test (CPET) is an underutilized tool for evaluating patients with dyspnea of uncertain etiology. This is often due to the daunting task of trying to make sense of seemingly large amounts of interacting data, along with clinicians not having been taught a systematic approach for interpreting the results. Unlike other typical tests we order that point to a specific laboratory or anatomic radiographic abnormality, narrowing our differential to a few possibilities, one needs a different mindset when interpreting a CPET. This is a study to demonstrate the body's normal or abnormal physiologic responses to increasing levels of physical stress. Because different conditions can give similar findings, the physiologic abnormalities must be interpreted in the context of the clinical presentation. If the results do not entirely fit the suspected diagnosis, they should be reported in a manner that may help guide the ordering physician down an alternate pathway. This CHEST NetWork has sought ways to reach out to members to promote a better understanding of the basics of pulmonary physiology in the management of patients. We created an online two-part video demonstrating a basic systematic approach toward understanding the combinations of findings one often sees when performing a CPET. A comprehensive understanding cannot be shown in a 40-minute video series, but, hopefully, this will give a starting point to make this task easier and more enjoyable.

Zachary Morris, MD, FCCP
Steering Committee Member

Pulmonary Vascular Disease BMPR2 mutation regulates singular millimetric fibrovascular lesions in bronchial circulation in PAH

Patients with PAH with BMPR2 mutation are younger with worse hemodynamics, ie, higher mean PAP with higher PVR and a lower cardiac index in comparison to the noncarriers. A systematic analysis of pulmonary imaging using CT angiography or magnetic resonance imaging in patients with PAH demonstrated increased bronchial arterial hypertrophy in BMPR2 mutation carriers compared with those without the mutation. Moreover, hemoptysis is more frequently encountered in patients with PAH with BMPR2 mutation and presumably related to bronchial artery remodeling and angiogenesis. French investigators described, in histopathology findings of explanted lungs of 44 patients with PAH (23 carriers of BMPR2 and 21 noncarriers), unusual singular millimetric fibrovascular lesions (SiMFi) in patients with BMPR2 mutations. The SiMFi is a structure of millimetric dimension with fibrovascular characteristics that are extremely rich in collagen and displayed more than one vascular channel. SiMFi did not show a classic glomeruloid pattern with predominant endothelial cell proliferation as seen in pleomorphic lesions but rather a large conglomerate of hypertrophic vessels. Performing an ink injection experiment in a freshly explanted lung highlighted a patent connection between bronchial/systemic vessels and pulmonary septal veins. SiMFi had an increased amount of bronchial microvessels and showed increased hypertrophy of larger bronchial arteries. SiMFi is directly related to hypertrophy and/or angiogenesis of vascular/lung/spacebronchial arteries in the vicinity of the diseased artery. In patients with PAH with BMPR2 mutations, bronchial angiogenesis is more prevalent compared with patients with PAH lacking these mutations. This highlights the role of bronchial arteries in the spectrum of PAH.

Hector Caigas, MD, FCCP
Sandeep Sahay, MD, FCCP
Steering Committee Members

References

Thoracic Oncology
We have a lung cancer screening test but we could use it better

The American Lung Association recently demonstrated the majority of current and former smokers don’t know about lung cancer screening (LCS) with low-dose CT scanning.1 Researchers estimate less than 5% of eligible persons received LCS.2 Awareness campaigns targeting patients and health care providers at the local level can improve LCS uptake.3,4 While any new clinical practice has an expected implementation delay, LCS has another implementation barrier: complex eligibility criteria (age 55 – 80 years PLUS quit time less than 15 years). Electronic health record (EHR) tools might accelerate the adoption curve to identify eligible persons.5 Moreover, assessing and recording a qualitative smoking history is challenging, at best. One center showed 96.2% discordance between EHR smoking history and that obtained during shared decision-making visit for LCS.6 Mostly, the EHR underreported quantitative pack-year history; meaning LCS-eligible patients might fail to be identified by EHR review alone. Another small pilot showed that some patients age 55 – 79 now rely on the EHR to update their smoking history using patient portal, but this will not be effective for all patients.7 For current smokers, age alone may be an effective identification strategy, given the average start time for most smokers.8

Even though current LCS guidelines leave out some individuals at high risk for lung cancer, we must continue efforts to offer this potentially life-saving service to patients now eligible. Using EHR tools may help proactively identify those who are eligible for lung cancer screening.

Abbie Begnaud, MD
NetWork Member

References

In Memoriam
CHEST has been informed of the following members’ deaths. We extend our sincere condolences to friends and family.

Nagesh V Salian, MD, FCCP
(2016)

Ted A Calinoog, MD, FCCP
(2017)

Azam Ansari, MD
(2017)

Arthur E. Schmidt, MD, FCCP
(2017)

W. Gerald Rainer, MD, FCCP
(2017)
2-hour PE treatment time

8mg tPA dose

23–26% reduction RV/LV ratio

2% PE recurrence at one year

2% mortality at one year

35% improved PE QOL score at one year

WHEN IT COMES TO EVIDENCE, MORE IS MORE.

Now there are 12 months of data to support 2-hour EKOS® PE treatment.*

The OPTALYSE PE one-year data reinforces the safety and efficacy of EKOS® therapy using a tPA dose as low as 8mg. With very low mortality and bleeding rates, improved quality of life for your patients and greater flexibility for you—EKOS® is setting the standard in PE data.

Treat PE with EKOS®

Download the OPTALYSE PE study at www.ekoscorp.com

*Shirling K. “Long Term Results of the OPTALYSE PE trial” as presented at the International Symposium on Endovascular Therapy (ISET) meeting, Hollywood, FL. Feb 2018.

FDA CLEARED INDICATIONS: The EkoSonic® Endovascular System is indicated for ultrasound-facilitated, controlled, and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries. Instructions for use, including warnings, precautions, potential complications, and contraindications, can be found at www.ekoscorp.com. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician.

THE CE MARK (CE0086) HAS BEEN AFFIXED TO THE EKOSONIC® PRODUCT WITH THE FOLLOWING INDICATIONS:

Peripheral Vasculature: The EkoSonic® Endovascular Device, consisting of the Intelligent Drug Delivery Catheter (IDDC) and the MicroSonic™ Device (MSD), is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. All therapeutic agents utilized with the EkoSonic® Endovascular System should be fully prepared and used according to the instruction for use of the specific therapeutic agent. Pulmonary Embolism: The EKOS EkoSonic® Endovascular System is intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25mmHg) or echocardiographic evaluation.

EKOS CORPORATION | 11911 N. Creek Pkwy S. | Bothell, WA 98011 | 888.400.3567 | EKOSCORP.COM

EKOS and EkoSonic® are registered trademarks of EKOS Corporation, a BTG International group company. “Acoustic pulse thrombolysis” is a trademark of EKOS Corporation. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in US, EUL and certain other territories and trademarks of BTG International Ltd elsewhere. © 2018 EKOS Corporation. NA-END-20180616